HCC
MCID: HPT023
MIFTS: 92

Hepatocellular Carcinoma (HCC) malady

Categories: Genetic diseases, Rare diseases, Liver diseases, Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Hepatocellular Carcinoma

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 35LifeMap Discovery®, 37MedGen, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 52 35 11 54 70 12 50 13
Liver Cancer 11 70 38 13
Liver Neoplasm 11 27 13
Hepatoma 11 70 13
Hcc 11 54 70
Adult Primary Hepatocellular Carcinoma 11 68
Primary Malignant Neoplasm of Liver 11 68
Malignant Neoplasm of Liver 11 68
Hepatoblastoma, Somatic 52 12
Hepatocellular Cancer 70 27
Primary Liver Cancer 11 48
Liver Neoplasms 39 68
Hepatic Cancer 11 50
Hepatoblastoma 54 68
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 11
Epithelial Hepatic and Intrahepatic Bile Duct Neoplasm 11
Rare Tumor of Liver and Intrahepatic Biliary Tract 48
Non-Resectable Primary Hepatic Malignant Neoplasm 11
Hepatocellular Carcinoma, Childhood Type, Somatic 52
Liver and Intrahepatic Biliary Tract Carcinoma 68
Resectable Malignant Neoplasm of the Liver 11
 
Primary Malignant Neoplasm of Liver Nos 11
Malignant Neoplasm of Liver Unspecified 11
Resectable Malignant Neoplasm of Liver 11
Malignant Neoplasm of Liver, Primary 11
Hepatocellular Carcinoma, Somatic 52
Malignant Hepato-Biliary Neoplasm 11
Primary Malignant Liver Neoplasm 48
Malignant Hepatobiliary Neoplasm 68
Hepatocellular Cancer, Somatic 52
Primary Tumor of the Liver 48
Carcinoma, Hepatocellular 39
Malignant Tumor of Liver 11
Primary Liver Carcinoma 48
Primary Cancer of Liver 48
Liver Cell Carcinoma 70
Ca Liver - Primary 11
Neoplasm of Liver 11
Hepatic Neoplasm 11
Liver Carcinoma 68
Adult Hepatoma 11
Lcc 70

Characteristics:

Orphanet epidemiological data:

54
hepatoblastoma:
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile
hepatocellular carcinoma:
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: adult

HPO:

64
hepatocellular carcinoma:
Inheritance: autosomal dominant inheritance, heterogeneous, somatic mutation

Classifications:

Orphanet: 54 
Rare hepatic diseases


External Ids:

OMIM52 114550
Disease Ontology11 DOID:3571, DOID:684, DOID:916
ICD1030 C22.0, C22.9
ICD9CM32 155.0, 155.2
MESH via Orphanet40 D018197, D006528
UMLS via Orphanet69 C0206624
ICD10 via Orphanet31 C22.2, C22.0

Summaries for Hepatocellular Carcinoma

About this section
MedlinePlus:38 Your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. primary liver cancer starts in the liver. metastatic liver cancer starts somewhere else and spreads to your liver. risk factors for primary liver cancer include having hepatitis b or c heavy alcohol use having cirrhosis, or scarring of the liver having hemochromatosis, an iron storage disease obesity and diabetes symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. however, you may not have symptoms until the cancer is advanced. this makes it harder to treat. doctors use tests that examine the liver and the blood to diagnose liver cancer. treatment options include surgery, radiation, chemotherapy, or liver transplantation. nih: national cancer institute

MalaCards based summary: Hepatocellular Carcinoma, also known as liver cancer, is related to glycogen storage disease and colorectal cancer, and has symptoms including hepatosplenomegaly, icterus and abdominal pain. An important gene associated with Hepatocellular Carcinoma is AXIN1 (Axin 1), and among its related pathways are ERK Signaling and Pathways in cancer. The drugs interferon alfa-2b and recombinant interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and t cells, and related mouse phenotypes are Increased shRNA abundance (Z-score > 2) and neoplasm.

UniProtKB/Swiss-Prot:70 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

OMIM:52 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common... (114550) more...

Disease Ontology:11 A liver carcinoma that has material basis in undifferentiated hepatocytes.

Wikipedia:71 Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the most common type of liver cancer. more...

Related Diseases for Hepatocellular Carcinoma

About this section

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 398)
idRelated DiseaseScoreTop Affiliating Genes
1glycogen storage disease31.0AFP, APC, CTNNB1, MET, MYC, TP53
2colorectal cancer30.6APC, AXIN1, CASP8, CCND1, CTNNB1, IGF2R
3peritoneal mesothelioma30.2CCND1, CTNNB1, MET, MYC, PIK3CA, TP53
4cystadenoma29.8CASP8, MYC, TP53
5childhood hepatocellular carcinoma12.3
6mixed fibrolamellar hepatocellular carcinoma12.1
7fibrolamellar carcinoma12.0
8adult hepatocellular carcinoma12.0
9aflatoxins-related hepatocellular carcinoma11.8
10ruijs-aalfs syndrome11.7
11tyrosinemia, type i11.4
12hepatitis c virus11.4
13liver sarcoma11.3
14hepatoid adenocarcinoma11.2
15pityriasis rotunda11.2
16lethal congenital contracture syndrome11.2
17hepatitis11.0
18lung large cell carcinoma11.0
19cholestasis, progressive familial intrahepatic 210.9
20citrullinemia, adult-onset type ii10.9
21hepatocellular clear cell carcinoma10.9
22sclerosing hepatic carcinoma10.9
23hepatitis b10.8
24lethal congenital contracture syndrome 110.8
25cerebroretinal microangiopathy with calcifications and cysts10.8
26leukoencephalopathy, cerebral calcifications, and cysts10.8
27cardiomyopathy, dilated, 1h10.8AFP, APC, AXIN1, CASP8, CCND1, CDKN3
28hepatitis c10.7
29proctitis10.7AFP, CCND1, CTNNB1, MET, MYC, PIK3CA
30malignant pleural solitary fibrous tumor10.6AFP, CCND1, CTNNB1, MYC, TP53, VEGFA
31trachea squamous cell carcinoma10.6CCND1, CTNNB1, MYC, PIK3CA, TP53, VEGFA
32placenta praevia10.6CCND1, CTNNB1, MYC, PIK3CA, TP53, VEGFA
33split-hand/foot malformation with long bone deficiency 110.6CASP8, CCND1, CDKN3, CTNNB1, MET, MYC
34nail disorder, nonsyndromic congenital, 3,10.6CCND1, CTNNB1, MYC, PIK3CA, TP53, VEGFA
35basal cell carcinoma 710.6CASP8, CCND1, CTNNB1, MET, MYC, PIK3CA
36bardet-biedl syndrome10.6CCND1, CTNNB1, MYC, TP53, VEGFA
37nevoid hypermelanosis, linear and whorled10.6CCND1, CTNNB1, MYC, TP53, VEGFA
38muscular dystrophy-dystroglycanopathy , type b, 210.6APC, CCND1, CTNNB1, MYC, PIK3CA, TP53
39asperger syndrome10.6APC, AXIN1, CCND1, CTNNB1, MYC, TP53
40glucose-6-phosphate translocase deficiency10.6MET, MYC, PIK3CA, TP53, VEGFA
41cleft palate cardiac defect ectrodactyly10.6CCND1, MET, TP53, VEGFA
42hemorrhagic proctocolitis10.6CCND1, CTNNB1, MYC, PIK3CA
43systemic lupus erythematosus with nephritis 210.6APC, CASP8, CCND1, CTNNB1, IGF2R, MET
44gastroesophageal junction adenocarcinoma10.6AFP, CCND1, CTNNB1, TP53
45malignant ovarian mixed epithelial neoplasm10.6AFP, APC, CTNNB1, HNF1A, TP53
46pearson syndrome10.6CCND1, CTNNB1, TP53, VEGFA
47breast malignant phyllodes tumor10.6CCND1, CTNNB1, MET, TP53
48adult medulloblastoma10.6CCND1, MYC, TP53, VEGFA
49basal cell nevus syndrome10.6APC, AXIN1, CASP8, CTNNB1, MET, MYC
50facial dermatosis10.6AFP, CCND1, CTNNB1, TP53

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Deficiency AnemiaAlcoholic Liver Cirrhosis
Portal HypertensionProtein-Energy Malnutrition
Intrahepatic Gall Duct CancerAcute Cystitis
Hepatic EncephalopathyActive Peptic Ulcer Disease

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to hepatocellular carcinoma

Symptoms & Phenotypes for Hepatocellular Carcinoma

About this section

Symptoms by clinical synopsis from OMIM:

114550

Clinical features from OMIM:

114550

Human phenotypes related to Hepatocellular Carcinoma:

 64
id Description HPO Frequency HPO Source Accession
1 hepatocellular carcinoma64 HP:0001402
2 micronodular cirrhosis64 HP:0001413
3 subacute progressive viral hepatitis64 HP:0006572

UMLS symptoms related to Hepatocellular Carcinoma:


hepatosplenomegaly, icterus, abdominal pain, fever, malaise, constipation, diarrhea, dyspepsia, heartburn, nausea and vomiting, gastrointestinal gas

GenomeRNAi Phenotypes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-19210.8APC, CTNNB1, IGF2R, PEG10, PIK3CA, CASP8

MGI Mouse Phenotypes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

41 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000200611.5AFP, APC, CASP8, CCND1, CTNNB1, MET
2MP:001076811.5AFP, APC, AXIN1, CASP8, CCND1, CTNNB1
3MP:000538211.4APC, AXIN1, CCND1, CTNNB1, IGF2R, MET
4MP:000537811.4APC, AXIN1, CASP8, CCND1, CTNNB1, FGL1
5MP:000538911.4AFP, APC, AXIN1, CCND1, CTNNB1, HNF1A
6MP:000537611.4AFP, APC, CASP8, CCND1, CTNNB1, FGL1
7MP:000538011.4APC, AXIN1, CASP8, CTNNB1, IGF2R, MET
8MP:000538411.4APC, AXIN1, CASP8, CCND1, CTNNB1, HNF1A
9MP:000538611.4AFP, APC, AXIN1, CCND1, CTNNB1, FGL1
10MP:000539011.3APC, AXIN1, CCND1, CTNNB1, FGL1, HNF1A
11MP:000538511.3APC, AXIN1, CASP8, CCND1, CTNNB1, IGF2R
12MP:000536711.3APC, AXIN1, CASP8, CTNNB1, HNF1A, IGF2R
13MP:000537911.3AFP, APC, CASP8, CCND1, CTNNB1, HNF1A
14MP:000538711.2APC, CASP8, CCND1, CTNNB1, MET, MTUS1
15MP:000537111.2APC, AXIN1, CTNNB1, IGF2R, MET, MYC
16MP:000287311.2APC, AXIN1, CCND1, CTNNB1, IGF2R, MET
17MP:000536911.1APC, CASP8, CTNNB1, HNF1A, MET, MYC
18MP:000538111.1APC, AXIN1, CCND1, CTNNB1, HNF1A, MET
19MP:000537011.1AFP, APC, CASP8, CTNNB1, FGL1, HNF1A
20MP:000363111.1APC, AXIN1, CASP8, CCND1, CTNNB1, IGF2R
21MP:000538811.1AXIN1, CASP8, CCND1, CTNNB1, IGF2R, MET
22MP:001077111.1APC, CASP8, CCND1, CTNNB1, HNF1A, MYC
23MP:000537510.9APC, FGL1, HNF1A, MYC, PIK3CA, STARD13
24MP:000301210.9APC, CTNNB1, HNF1A, MET, MYC, PIK3CA

Drugs & Therapeutics for Hepatocellular Carcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Feridex I.V.16 FERUMOXIDES Advanced Magnetics February 1996
FDA Label: -
Disease/s that Drug Treats:liver cancer
Indications and Usage:16 -
DrugBank Targets: -
Mechanism of Action:16 
Target: -
Action: -
FDA: -
2
Nexavar16 44 SORAFENIB TOSYLATE Bayer/Onyx December 2005
FDA Label: Nexavar
Disease/s that Drug Treats:Renal Cell Carcinoma
Indications and Usage:16 NEXAVAR is a kinase inhibitor indicated for the treatment of Unresecta ble hepatocellular carcinoma (1.1) adjust thyroid repla cement therapy in patients with thyroid ca ncer. (5.12) Advanced renal cell carcinoma (1.2) Locally recurrent or meta static, progressive, differentiated thyroid carcinoma refractory to ra dioactive iodine treatment (1.3)
DrugBank Targets:14 1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Vascular endothelial growth factor receptor 3;4. Vascular endothelial growth factor receptor 2;5. Receptor-type tyrosine-protein kinase FLT3;6. Platelet-derived growth factor receptor beta;7. Mast/stem cell growth factor receptor Kit;8. Fibroblast growth factor receptor 1;9. Proto-oncogene tyrosine-protein kinase receptor Ret;10. Vascular endothelial growth factor receptor 1
Mechanism of Action:16 
Target: c-CRAF, BRAF and mutant BRAF, KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß
Action: inhibitor
FDA: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro.Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surfacekinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of thesekinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumorgrowth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumorangiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosiswer e obser ved in models of HCC, RCC, and DTC.

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 929)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Adefovir Dipivoxilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1134142340-99-660871
Synonyms:
(((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate
((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid, diester with hydroxymethyl pivalate
142340-99-6
9-(2-((-Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine
9-(2-((Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine
AC-1693
AC1L1U36
ADEFOVIR DIPIVOXIL
ADV
AKOS005145737
Adefovir
Adefovir Pivoxil
Adefovir dipivoxil (USAN)
Adefovir pivoxil
Adefovir pivoxil (JAN)
Adefovirdipivoxl
Adefovirum
Adéfovir
Ambap142340-99-6
Bis(POM)-PMEA
Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine
Bis(pom)PMEA
Bis-POM PMEA
Bis-POM PMEA, Adefovir Dipivoxil
Bis-POM PMEA, Preveon, Hepsera, Adefovir Dipivoxil
C20H32N5O8P
CHEMBL922
 
CID60871
D01655
DB00718
FT-0082875
GS 0840
GS 840
GS-0840
GS-840
Hepsera
Hepsera (TM)
Hepsera (TN)
I06-1150
I14-3234
LS-173141
MolPort-003-986-417
NCGC00164624-01
PMEA
Piv2PMEA
Preveon
Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester
Propanoic acid,2,2-dimethyl-(((2-(6-amino-9H-purin-9-yl)ehtoxy)mehtyl)phosphinyldiene)bis(oxymehtylene)ester
S1718_Selleck
TL8000938
UNII-U6Q8Z01514
YouHeDing
ZINC03930376
[2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
adefovir depivoxil
bis-POM PMEA
2
IronapprovedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 111657439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
3
Propranololapproved, investigationalPhase 4, Phase 3, Phase 2228525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
InnoPranXL
 
Innopran XL
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
4
NadololapprovedPhase 4, Phase 32242200-33-939147
Synonyms:
(2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol
(2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol
42200-33-9
5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol
AC1L2151
AC1Q1MO3
AC1Q77IZ
Anabet
BRD-A87606379-001-03-4
BSPBio_003152
CCRIS 1048
CHEMBL649
CID39147
CPD000058975
Corgard
Corgard (TN)
Corgaretic
D00432
D009248
DB01203
DivK1c_000427
EINECS 255-706-3
HMS1570D17
HMS1922O05
HMS2093A15
HMS501F09
HSDB 6532
IDI1_000427
KBio1_000427
KBio2_002123
KBio2_004691
KBio2_007259
 
KBio3_002652
KBioGR_000765
KBioSS_002123
LS-94578
MLS000028580
MLS001148087
MolPort-003-666-474
NCGC00089811-02
NINDS_000427
Nadic
Nadolol (JP15/USP/INN)
Nadolol [USAN:BAN:INN:JAN]
Nadololum
Nadololum [INN-Latin]
Prestwick0_000818
Prestwick1_000818
Prestwick2_000818
Prestwick_108
SAM002264627
SMP1_000203
SMR000058975
SPBio_001392
SPBio_002636
SPECTRUM1503260
SQ 11725
SQ-11725
SQ11725
Solgol
Spectrum2_001546
Spectrum3_001586
Spectrum4_000193
Spectrum5_001255
Spectrum_001643
UNII-FEN504330V
VU0239635-6
nadolol
5
CisplatinapprovedPhase 4, Phase 2, Phase 3, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
6
Sufentanilapproved, investigationalPhase 418556030-54-741693
Synonyms:
56030-54-7
60561-17-3 (citrate)
AC1L26AJ
AC1Q5I7B
C08022
C22H30N2O2S
CHEBI:127638
CHEBI:9316
CHEMBL658
CID41693
Chronogesic
D05938
DB00708
HSDB 6760
L000580
LS-175693
MolPort-004-286-008
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide
 
N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide
N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide
Oprea1_120838
Oprea1_246787
PDSP1_001741
PDSP2_001724
R 30730
R-30730
SUFENTANIL
Sufentanil
Sufentanil (USAN/INN)
Sufentanil Citrate
Sufentanil [USAN:BAN:INN]
Sufentanilo
Sufentanilum
Sufentanilum [INN-Latin]
Sufentanyl
Sulfentanil
Sulfentanyl
UNII-AFE2YW0IIZ
7
Doxorubicinapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
8
EpirubicinapprovedPhase 4, Phase 2, Phase 3, Phase 139456420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
9
TamoxifenapprovedPhase 4, Phase 3, Phase 2, Phase 139010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
10
Telbivudineapproved, investigationalPhase 4, Phase 1, Phase 2863424-98-4159269
Synonyms:
1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione
1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione
1-(2-Deoxy-beta-L-ribofuranosyl)-5-methyluracil
1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
2'-Deoxy-L-thymidine
3424-98-4
AC-5632
AC1L4LJI
Beta-l-thymidine
CHEBI:17748
CHEMBL374731
CID159269
D06675
DB01265
Epavudine
I14-8810
L-DT
L-Deoxythymidine
L-Thymidine
L-dT
L-deoxythymidine
L-thymidine
 
LDT
LDT-600
LDT600
LLT
LS-186402
LS-187347
LdT
NB 02B
NV 02B
NV-02B
S1651_Selleck
Sebivo
Telbivudin
Telbivudine
Telbivudine (USAN/INN)
Telbivudine [USAN]
Tyzeka
Tyzeka (TN)
Tyzeka, Sebivo, Telbivudine
UNII-2OC4HKD3SF
ZINC00002159
beta-L-2'-Deoxythymidine
beta-L-Thymidine
11
lanreotideapprovedPhase 4, Phase 2, Phase 386108736-35-2
Synonyms:
Lanreotide
 
Lanreotide acetate
Somatuline Depot
12
SomatostatinapprovedPhase 4, Phase 3, Phase 223738916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
13
rituximabapprovedPhase 4, Phase 3, Phase 2, Phase 11692174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
14
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
15
Bevacizumabapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 12020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
16
Coal tarapprovedPhase 4, Phase 3, Phase 2, Phase 12028007-45-2
Synonyms:
 
Coal tars
Tar, coal
17
Oxaliplatinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
18
Tramadolapproved, investigationalPhase 424127203-92-533741
Synonyms:
(+)-(R,R)-trans-Tramadol
(+)-Tramadol
(+)-trans-2-(Dimethylaminomethyl)-1-(m-methoxyphenyl)cyclohexanol
(+)-trans-Tramadol free ba
(1R,2R)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexan-1-ol
(1R,2R)-2-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexanol
(1R,2R)-2-[(dimethylamino)methyl]-1-[3-(methyloxy)phenyl]cyclohexanol
27203-92-5
AC1L1Q6E
AC1Q59O2
AKOS005066335
Amanda
Amanda (TN)
BIDD:GT0075
C07153
CHEMBL1066
CID33741
Crispin
D08623
DB00193
EINECS 248-319-6
HMS2090D10
Jsp005295
LS-57115
 
LS-57116
MLS000333190
MolPort-002-507-778
NCGC00159343-02
Ralivia ER
Ralivia Flashtab
Ralivia flashtab
SMR000436547
STOCK4S-19075
Tradonal odis
Tramadol
Tramadol (INN)
Tramadol HCl
Tramadol HCl BP/EP
Tramadol [INN:BAN]
Tramadol hydrochloride
Tramadolum
Tramadolum [INN-Latin]
Tramal
Tramodol Hcl
Tridural
UNII-39J1LGJ30J
Ultram
Ultram ER
Zydol
tramadol
19
PravastatinapprovedPhase 4, Phase 3, Phase 215081093-37-054687
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
BIDD:GT0773
BRD-K60511616-236-01-4
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
FT-0082682
KS-5015
LS-94713
Lipostat
Mevalothin
Mevalotin
Mevastatin
Mevinolin
 
Oliprevin
Pravachol
Pravaselect
Pravastatin (INN)
Pravastatin Sodium
Pravastatin Sodium Salt
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin sodium
Pravastatin tert-Octylamine Salt
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS-431
SQ-31,000
Selectin
Selektine
Selipran
UNII-KXO2KT9N0G
Vasten
nchembio.301-comp7
nchembio790-comp15
pravastatin
pravastatina
pravastatine
pravastatinum
20
BenzocaineapprovedPhase 4, Phase 3, Phase 2, Phase 120161994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
21
Irinotecanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1112397682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
22
CetuximabapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1752205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
23
LevoleucovorinapprovedPhase 4, Phase 3, Phase 2, Phase 172868538-85-2
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
 
(S)-Leucovorin
Citrovorum factor
L-Folinic acid
Levofolene
Levofolinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
24
Erythromycinapproved, vet_approvedPhase 4, Phase 299114-07-812560
Synonyms:
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
,10-dione
114-07-8
3''-O-demethylerythromycin
374700-25-1
45673_FLUKA
45674_FLUKA
79235-06-6
82343-12-2
A/T/S
AC-12744
AC1L1FIQ
AC1L1QK7
AC1L1ZUR
AC1O8PVA
AC1Q2UA1
AC1Q6O1S
AI3-50138
AR-1A4414
AR-1H0723
Abboticin
Abomacetin
Acneryne
Acnesol
Ak-Mycin
Ak-mycin
Akne Cordes Losung
Akne-Mycin
Akne-mycin (TN)
Aknederm Ery Gel
Aknemycin
Aknin
AustriaS
BB_NC-1332
BIDD:GT0017
BPBio1_000312
BSPBio_000282
BSPBio_002480
Benzamycin
Benzamycin Pak
Bristamycin
C-Solve-2
C01912
C37H67NO13
CCRIS 9078
CHEBI:42355
CHEMBL532
CID12560
CID3255
CID6713919
CID8233
D00140
DB00199
Del-Mycin
Derimer
Deripil
DivK1c_000294
DivK1c_000397
DivK1c_000702
Dotycin
Dumotrycin
E- mycin, Erycin, Robimysin
E-Base
E-Base (base)
E-Glades
E-Mycin
E-Mycin (base)
E-Solve 2
E0751
E0774_SIAL
E5389_SIGMA
E6376_SIAL
E7904_SIGMA
EINECS 204-040-1
EM
EMU
ERY
ERYC
ERYC (base)
ERYTHROMYCIN STEARATE
ETS
Emgel
Emu-V
Emu-Ve
Emuvin
Emycin
Endoeritrin
Erecin
Erimycin-T
Erisone
Eritomicina
Eritrocina
Eritromicina
Eritromicina [INN-Spanish]
Ermycin
Eros
Ery-B
Ery-Diolan
Ery-Sol
Ery-Tab
Ery-Tab (base)
Ery-maxin
Eryacne
Eryacnen
Eryc
Eryc (TN)
Eryc 125
Eryc Sprinkles
Eryc-125
Eryc-250
Erycen
Erycette
Erycin
Erycinum
Eryderm
Erydermer
Erygel
Erygel (TN)
Eryhexal
Erymax
Erymed
Erypar
Erysafe
Erytab
Erythra-Derm
Erythro
Erythro-Statin
Erythro-Teva
Erythrocin
Erythrocin Stearate
Erythroderm
Erythrogran
Erythroguent
Erythromast 36
Erythromid
Erythromycin
Erythromycin & VRC3375
Erythromycin (JP15/USP/INN)
 
Erythromycin A
Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279
Erythromycin B
Erythromycin C
Erythromycin Lactate
Erythromycin Ointment
Erythromycin Stearate
Erythromycin [INN:BAN:JAN]
Erythromycin base
Erythromycin estolate
Erythromycin ethylsuccinate
Erythromycin glucoheptonate
Erythromycin intravenous
Erythromycin lactobionate
Erythromycin oxime
Erythromycin sodium lauryl sulfate
Erythromycin, compd. with monododecyl sulfate, sodium salt
Erythromycine
Erythromycine [INN-French]
Erythromycinum
Erythromycinum [INN-Latin]
Erytop
Erytrociclin
Ethril 250
HMS1568O04
HMS1920M04
HMS2091D05
HMS500O16
HSDB 3074
I06-0245
IDI1_000294
IDI1_000397
IDI1_000702
Ilocaps
Ilosone
Ilosone (estolate)
Iloticina
Ilotycin
Ilotycin Gluceptate
Ilotycin T.S
Ilotycin T.S.
Inderm
Inderm Gel
IndermRetcin
KBio1_000294
KBio1_000397
KBio1_000702
KBio2_000555
KBio2_001139
KBio2_003123
KBio2_003707
KBio2_005691
KBio2_006275
KBioGR_001175
KBioSS_000555
KBioSS_001139
KST-1A8261
Kesso-Mycin
LMPK04000006
LS-187077
LS-64648
Latotryd
Lederpax
MLS001066618
Mephamycin
Mercina
MolPort-000-772-161
MolPort-002-507-378
MolPort-003-933-429
N-Methylerythromycin A
NCGC00179619-01
NCI-C55674
NINDS_000294
NINDS_000397
NINDS_000702
NSC 55929
NSC55929
Oftalmolosa Cusi Eritromicina
Oftamolets
PCE Dispertab (base)
Paediathrocin
Pantoderm
Pantodrin
Pantomicina
Pce
Pce (TN)
Pfizer-e
Pharyngocin
Prestwick0_000151
Prestwick1_000151
Prestwick2_000151
Prestwick3_000151
Prestwick_205
Primacine
Propiocine
Proterytrin
R-P Mycin
Retcin
Robimycin
Romycin
SBB057401
SMP1_000119
SMR000544946
SPBio_000778
SPBio_001226
SPBio_002221
SPECTRUM1500280
STK249736
Sans-acne
Sansac
Serp-AFD
Skid Gel E
Spectrum2_000759
Spectrum2_001263
Spectrum4_000538
Spectrum5_001596
Spectrum_000115
Spectrum_000659
Staticin
Staticin (TN)
Stiemicyn
Stiemycin
Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin
T-Stat
T-stat (TN)
Taimoxin-F
Theramycin Z
Tiloryth
Tiprocin
Torlamicina
UNII-63937KV33D
Udima Ery Gel
Wemid
Wyamycin S
adecane-2,10-dione (non-preferred name)
bmse000664
erythro
erythromycin
nchembio.285-comp13
érythromycine
25
Capecitabineapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 11342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
26
Triamcinoloneapproved, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1510124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
 
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triatex
Tricortale
Triderm
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
27
MentholapprovedPhase 4, Phase 3, Phase 2, Phase 126062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
28TegafurapprovedPhase 4, Phase 29617902-23-7
29
FluorouracilapprovedPhase 4, Phase 3, Phase 2, Phase 1185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
30
Ursodeoxycholic acidapproved, investigationalPhase 4, Phase 297128-13-231401
Synonyms:
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid
(3a,5b,7b)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
128-13-2
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
3,7-Dihydroxycholan-24-oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3a,7b-Dihydroxy-5b-cholan-24-oate
3a,7b-Dihydroxy-5b-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholanic acid
4-10-00-01604 (Beilstein Handbook Reference)
50809-41-1
5beta-Cholan-24-oic acid-3alpha,7beta-diol
5beta-Cholanic Acid-3alpha,7beta-diol
7-beta-Hydroxylithocholic acid
7beta-Hydroxylithocholic acid
80225-86-1
AB00513977
AC-18919
AC-2081
AC1L1LJH
Acide ursodesoxycholique
Acide ursodesoxycholique [INN-French]
Acido ursodeossicolico
Acido ursodeossicolico [Italian]
Acido ursodeoxicolico
Acido ursodeoxicolico [INN-Spanish]
Acidum ursodeoxycholicum
Acidum ursodeoxycholicum [INN-Latin]
Actigall
Actigall (TN)
Antigall
Arsacol
BB_NC-2372
BPBio1_001052
BRN 3219888
BSPBio_000956
C07880
C24H40O4
CCRIS 5502
CHEBI:9907
CHEMBL1551
CHEMBL73390
CID11516715
CID31401
CPD-10534
CPD000058403
Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI)
Cholit-ursan
D00734
DB01586
Delursan
Deoxyursocholic Acid
Destolit
Deursil
Dom-ursodiol c
EINECS 204-879-3
HMS1570P18
 
ISO-URSODEOXYCHOLIC ACID
IU5
LMST04010033
LS-53033
Litursol
Lyeton
MLS000028461
MLS001066373
MolPort-001-794-630
MolPort-005-932-884
NCGC00179363-01
NCI60_028904
NSC 657950
NSC 683769
PHL-ursodiol c
PMS-ursodiol c
Peptarom
Prestwick0_000958
Prestwick1_000958
Prestwick2_000958
Prestwick3_000958
S1643_Selleck
SAM002264653
SMP2_000012
SMR000058403
SPBio_003105
Sodium Ursodeoxycholate
Solutrat
U-9000
U0030
U5127_SIGMA
UDCA
UDCS
UNII-724L30Y2QR
URSODEOXYCHOLIC ACID
UrSO
Urosdesoxycholate
Urosdesoxycholic acid
Urosiol
Ursacholic Acid
Ursacol
Urso
Urso (TN)
Urso 250
Urso DS
Urso Forte
Ursobilin
Ursochol
Ursodamor
Ursodeoxy cholic acid
Ursodeoxycholate
Ursodeoxycholic acid
Ursodeoxycholic acid (JP15/INN)
Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol
Ursodeoxycholicacid
Ursodesoxycholic acid
Ursodexycholate
Ursodexycholic Acid
Ursodexycholic acid
Ursodiol
Ursodiol (USP)
Ursodiol [USAN]
Ursofalk
Ursolvan
Ursosan
chenodeoxycholic acid
ursodeoxycholate
ursodiol
31
Celecoxibapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 2444169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
32ParecoxibapprovedPhase 4, Phase 341198470-84-7
33
Tenofovirapproved, investigationalPhase 4, Phase 3759147127-20-6464205
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-9-(2-phosphonomethoxypropyl)adenine
(R)-PMPA
147127-20-6
206184-49-8
AC-760
AC1LA9BO
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
GNA & Tenofovir
GS 1275
GS 1278
GS1278
 
HHA & Tenofovir
KS-5021
MolPort-003-850-411
NCGC00167535-01
PMPA
PMPA-(R)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
S1401_Selleck
TDF
TFV
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir disoproxil
Tenofovir disoproxil fumarate
UNII-99YXE507IL
Viread
Viread, Tenofovir
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
34
Emtricitabineapproved, investigationalPhase 4, Phase 3457143491-57-060877
Synonyms:
(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-.beta.-L-FTC
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(-)-FTC
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-amino-5-Fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-amino-5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
.beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine
143491-54-7
143491-57-0
145213-48-5
2',3',5-FTC
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine
2'-Deoxy-5-fluoro-3'-thiacytidine
2-FTC
3'-Thia-2'.3'-dideoxy-5-fluorocytidine
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
4-amino-5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
524W91
AC1L1U3I
AC1Q4KUB
BW 1592
 
BW 524W91
BW-524W91
BW524W91
C122114
C12599
C8H10FN3O3S
CHEBI:31536
CHEMBL885
CID60877
Coviracil
Coviracil(TM)
D01199
DB00879
DRG-0208
Emtricitabin
Emtricitabina
Emtricitabine
Emtricitabine (JAN/USAN/INN)
Emtricitabinum
Emtriva
Emtriva (TN)
Emtriva(TM)
FT-0080009
HMS2089I05
HSDB 7337
LS-135838
LS-173184
NCGC00164564-01
RCV
Racivir
SBB066061
TL8000958
UNII-G70B4ETF4S
ZINC03629271
beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine
dOTFC
emtricitabine
35
Peginterferon alfa-2bapprovedPhase 4, Phase 3, Phase 230799210-65-8, 215647-85-1
Synonyms:
215647-85-1
D02748
PEG-Intron
PegIntron
 
Peginterferon alfa-2b
Peginterferon alfa-2b (INN)
Peginterferon alfa-2b (generical recombination)
Peginterferon alfa-2b (generical recombination) (JAN)
Pegintron (TN)
Unitron PEG
36
ColchicineapprovedPhase 4, Phase 211564-86-86167, 2833
Synonyms:
(S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide
30512-31-3
5843-86-7
64-86-8
7-alpha-H-Colchicine
7.alpha.H-Colchicine
7alphaH-Colchicine
AC1L1LXO
ACon1_000353
AI3-31149
AKOS001582887
BB_NC-0737
BPBio1_000535
BRD-K00259736-001-06-5
BSPBio_000485
BSPBio_002083
Benzo(a)heptalen-9(5H)-one
C 9754
C07592
C22H25NO6
C3915_SIGMA
C9754_SIGMA
CCRIS 691
CHEBI:27882
CHEMBL107
CID6167
CPD-9785
Colchicin
Colchicin [German]
Colchicina
Colchicina [Italian]
Colchicine (JP15/USP)
Colchicine (TN)
Colchicine [JAN]
Colchicine, (+-)-Isomer
Colchicine, (R)-Isomer
Colchicine, Colchicum autumnale
Colchicinum
Colchineos
Colchisol
Colchysat
Colcin
Colcrys
Colsaloid
Colstat
Condylon
D003078
D00570
DB01394
DB08117
DivK1c_000753
EINECS 200-598-5
EU-0100310
Goutnil
HMS1569I07
HMS1920A08
HMS2091G16
HMS502F15
HSDB 3044
IDI1_000753
KBio1_000753
KBio2_001322
KBio2_003890
 
KBio2_006458
KBio3_001303
KBioGR_000856
KBioSS_001322
Kolkicin
LOC
LS-279
Lopac0_000310
MEGxp0_001879
MLS001055448
MLS001055448-02
MLS001304089
MLS002153786
MPC-004
MolPort-001-742-594
N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)- acetamide
N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide
N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide
N-Acetyl trimethylcolchicinic acid methylether
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide
NCGC00025125-01
NCGC00025125-02
NCGC00025125-03
NCGC00025125-04
NCGC00025125-05
NCGC00025125-06
NCGC00025125-07
NCGC00025125-11
NCGC00169157-01
NCGC00169157-02
NCGC00169157-03
NCI60_041659
NChemBio.2007.10-comp20
NINDS_000753
NSC 757
NSC757
Prestwick0_000363
Prestwick1_000363
Prestwick2_000363
Prestwick3_000363
Prestwick_695
S2284_Selleck
SDCCGMLS-0066633.P001
SMR000058323
SPBio_000289
SPBio_002406
SPECTRUM1500205
Spectrum2_000075
Spectrum3_000362
Spectrum4_000298
Spectrum5_000787
Spectrum_000842
Tocris-1364
UNII-SML2Y3J35T
UPCMLD-DP065
UPCMLD-DP065:001
WLN: L B677 MV&T&J CO1 DO1 EO1 JMV1 NO1
ZINC00621853
binds to tubulin
colchicine
inhibits microtubular assembly
nchembio853-comp2
spindle poison
37
Tranexamic AcidapprovedPhase 4, Phase 2, Phase 32771197-18-85526
Synonyms:
08455_FLUKA
1197-17-7
1197-18-8
1ceb
3-14-00-00868 (Beilstein Handbook Reference)
4-(Aminomethyl)-Cyclohexanecarboxylic Acid
4-(Aminomethyl)cyclohexanecarboxylic acid
4-(aminomethyl)cyclohexane-1-carboxylic acid
857653_ALDRICH
A0236
AB00052260
AB1003647
AC-4687
AC1L1KJH
AC1Q50F3
AC1Q546D
AC1Q5U04
ALBB-006013
AMCA
AMCHA
AMH
AR-1F6595
Acide tranexamique
Acide tranexamique [INN-French]
Acido tranexamico
Acido tranexamico [INN-Spanish]
Acidum tranexamicum
Acidum tranexamicum [INN-Latin]
Amikapron
Amstat
Anvitoff
BAY 3517
BPBio1_000069
BRN 2207452
BSPBio_000061
BSPBio_002837
CAS-1197-18-8
CHEBI:48669
CHEMBL292500
CHEMBL877
CID5526
CL 65336
CL-65336
Carxamin
Cyclocapron
Cyklokapron
Cyklokapron (TN)
D01136
DB00302
DV 79
DV-79
DV79
DivK1c_000655
EINECS 214-818-2
Emorhalt
Exacyl
Frenolyse
HMS1568D03
HMS1921F08
HMS2092P03
HMS502A17
Hexapromin
Hexatron
I04-0993
IDI1_000655
KABI 2161
KBio1_000655
KBio2_001871
KBio2_004439
KBio2_007007
KBio3_002337
KBioGR_000511
 
KBioSS_001871
LS-56611
LS-56612
LT00159441
Mastop
MolPort-001-792-390
MolPort-002-512-008
NCGC00016569-01
NCGC00016569-02
NCGC00016569-03
NCGC00094944-01
NCGC00094944-02
NINDS_000655
NSC 291305
NSC291305
Oprea1_786414
Prestwick0_000171
Prestwick1_000171
Prestwick2_000171
Prestwick3_000171
Prestwick_476
RP 18,429
Rikavarin
Rikavarin (TN)
Rikavarin-S
SPBio_000689
SPBio_001982
SPECTRUM1502026
STK503668
STOCK1N-16183
Spectrum2_000655
Spectrum3_001189
Spectrum4_000046
Spectrum5_001258
Spectrum_001391
Spiramin
Tamcha
Tranex
Tranexamate
Tranexamic acid (JP15/USAN/INN)
Tranexamic acid [USAN:INN:BAN:JAN]
Tranexamic acid cis-form
Tranexamsaeure
Tranexan
Tranexmic acid
Tranhexamic acid
Trans AMCHA
Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid
Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid
Trans-p-(Aminomethyl)cyclohexanecarboxylic
Transamin
Transamin (TN)
Transamlon
Trasamlon
UNII-6T84R30KC1
Ugurol
WLN: L6TJ AVQ D1Z -T
cis-4-(Aminomethyl)cyclohexanecarboxylic acid
cis-4-Aminomethylcyclohexane-1-carboxylic acid
cis-AMCHA
t-AMCHA
tranexamic acid
tranexmic acid
trans-1-Aminomethylcyclohexane-4-carboxylic acid
trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid
trans-4-(Aminomethyl)cyclohexane-carboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester
trans-4-Aminomethylcyclohexane-1-carboxylic acid
trans-4-aminomethylcyclohexane-1-carboxylic acid
trans-Amcha
trans-Tranexamic acid
trans-p-(Aminomethyl)cyclohexanecarboxylic acid
38
Morphineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1100757-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
39
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
40
Trastuzumabapproved, investigationalPhase 4, Phase 2, Phase 1784180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
41
EthanolapprovedPhase 4, Phase 3, Phase 2, Phase 1213764-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
42
Pioglitazoneapproved, investigationalPhase 4, Phase 2441111025-46-84829
Synonyms:
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
105355-27-9
111025-46-8
198077-89-3
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
AB1004597
AC-1021
AC1L1J1Q
AD 4833
AD-4833
Actos
Actos (TN)
Actost
BRD-A48430263-003-02-4
BSPBio_002723
C07675
C19H20N2O3S
CHEBI:8228
CHEMBL595
CID4829
D08378
DB01132
Duetact
Glustin
HMS2089H14
HS-0047
 
HSDB 7322
I06-0089
KBio2_002103
KBio2_004671
KBio2_007239
KBio3_001943
KBioGR_001619
KBioSS_002103
LS-151327
MolPort-002-508-211
NCGC00163128-01
NCGC00163128-02
Pioglitazona
Pioglitazona [INN-Spanish]
Pioglitazone
Pioglitazone HCl
Pioglitazone Hydrochloride
Pioglitazone [BAN:INN]
Pioglitazone [Ban:Inn]
Pioglitazone [INN:BAN]
Pioglitazonum
Pioglitazonum [INN-Latin]
SPBio_001897
Spectrum2_001679
Spectrum3_001002
Spectrum4_001130
Spectrum5_001480
Spectrum5_002067
Spectrum_001623
U 72107
U 72107A
U-72107
U72,107A
UNII-X4OV71U42S
Zactos
nchembio790-comp10
pioglitazone (INN)
pioglitazone HCl
43
Aspirinapproved, vet_approvedPhase 4, Phase 3, Phase 2115250-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide acetylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
 
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
acide 2-(acétyloxy)benzoïque
acide acétylsalicylique
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
salicylic acid acetate
ácido acetilsalicílico
44
Peginterferon alfa-2aapproved, investigationalPhase 4, Phase 3, Phase 2565198153-51-45360545
Synonyms:
198153-51-4
D02747
Pegasys
Pegasys (TN)
 
Peginterferon alfa-2a
Peginterferon alfa-2a (USAN/INN)
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
Pegylated interferon alfa-2a
Pegylated interferon alpha2a
45
Heparinapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 18489005-49-6772, 46507594
Synonyms:
101921-26-0
102-94-3
102785-31-9
104521-37-1
11078-24-3
11129-39-8
12656-11-0
2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose
37324-73-5
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L19ZN
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
AR-1E4539
Allocinnamic acid
Ardeparin
Ardeparin sodium
Arteven
Bemiparin
Bemiparin sodium
CID772
CID8784
CY 216
Calciparine
Certoparin
Clexane
Clivarin
Clivarine
Cy 222
D006495
D017984
DB00407
DB01225
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
EMT 966
EMT 967
EMT-966
EMT-967
EMT966
EMT967
Enoxaparin
Enoxaparin sodium
Enoxaparine
Eparina
Eparina [DCIT]
FR 860
Fluxum
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
HSDB 3094
Hed-heparin
Hep Flush Kit in plastic container
Hep-Lock
Hep-Lock U/P
Hep-lock
Heparin
Heparin CY 216
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin Sodium
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
 
Heparin sodium 25,000 units in dextrose 5%
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sulfate
Heparin sulphate
Heparin, Low Molecular Weight
Heparin, Low-Molecular-Weight
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Inno-Hep
Innohep
Isocinnamic acid
KB 101
Kabi 2165
LHN 1
LMWH
Lioton 1000
Lipo-hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Lovenox
Lovenox HP
Low Molecular Weight Heparin
Low molecular weight heparin
Low molecular weight heparin sodium
Low-Molecular-Weight Heparin
Minolteparin sodium
MolPort-003-760-257
Multiparin
NSC174025
Nadroparin
Nadroparine
Novoheparin
OP 386
OP 622
Octaparin
PK 10,169
PK-10,169
PK-10169
PK10,169
PK10169
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Unfractionated heparin
Vetren
Vitrum AB
WY 90493RD
alpha-Heparin
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
enoxaparin
heparin
46
Mycophenolate mofetilapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 2952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
47
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
48
RibavirinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1100336791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
NSC 163039
 
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
49
CarboplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
50
Lamivudineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1621134678-17-460825
Synonyms:
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-SddC
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
3'-Thia-2',3'-dideoxycytidine
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
480434-79-5
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH-189
BCH-790
BCH189
BIDD:GT0033
Bio-0652
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
 
DB00709
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714X
GR-109714X
GR109714X
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
Hepitec
Heptivir
Heptodin
Heptovir
L0217
LMV
LS-2107
Lamivir
Lamivudin
Lamivudina
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-Isomer
Lamivudinum
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
ZINC00012346
Zeffix
Zefix
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
lamivudine

Interventional clinical trials:

(show top 50)    (show all 3484)
idNameStatusNCT IDPhase
1Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular CarcinomaUnknown statusNCT01570166Phase 4
2Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan CriteriaUnknown statusNCT01570075Phase 4
3Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular CarcinomaUnknown statusNCT00555334Phase 4
4Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor ThrombosisUnknown statusNCT01350206Phase 4
5Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular CarcinomaUnknown statusNCT00834860Phase 4
6Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular CarcinomaUnknown statusNCT00557024Phase 4
7TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular CarcinomaUnknown statusNCT00556803Phase 4
8Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cmUnknown statusNCT01351194Phase 4
9Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular CarcinomaUnknown statusNCT01833299Phase 4
10Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular CarcinomaUnknown statusNCT00768157Phase 4
11Trial of Ablation of Small Hepatocellular Carcinomas in Patients of CirrhosisUnknown statusNCT01438437Phase 4
12A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCCUnknown statusNCT01997957Phase 4
13Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular CarcinomaUnknown statusNCT01415063Phase 4
14Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular CarcinomaUnknown statusNCT00554905Phase 4
15Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) TherapyUnknown statusNCT01102335Phase 4
16Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal VaricesUnknown statusNCT01970748Phase 4
17Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular CarcinomaUnknown statusNCT01451658Phase 4
18Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA ReplicationUnknown statusNCT01894269Phase 4
19A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular CarcinomaUnknown statusNCT01758679Phase 4
20A Trial of EVL\GVS Alone vs. EVL\GVS Combined PropranololUnknown statusNCT01298284Phase 4
21Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV InfectionUnknown statusNCT00810524Phase 4
22Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal RebleedingUnknown statusNCT00567216Phase 4
23Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal CancerUnknown statusNCT01038154Phase 4
24Cholestatic Drug-induced Liver InjuryUnknown statusNCT01141322Phase 4
25Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related CirrhosisUnknown statusNCT00663182Phase 4
26Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders.Unknown statusNCT00179413Phase 4
27Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal CancerUnknown statusNCT01972503Phase 4
28Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal CancerUnknown statusNCT01564810Phase 4
29Parenteral Fish Oil in Major Laparoscopic Abdominal SurgeryUnknown statusNCT01819961Phase 4
30New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, ObstructionUnknown statusNCT01307878Phase 4
31Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver DiseaseUnknown statusNCT00941642Phase 4
32Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver MetastasisUnknown statusNCT01962376Phase 4
33Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal CancerUnknown statusNCT00868569Phase 4
34Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerUnknown statusNCT00274885Phase 4
35Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal CancerUnknown statusNCT00874406Phase 4
36Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal CancerUnknown statusNCT01972490Phase 4
37Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?Unknown statusNCT01101750Phase 4
38Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver InjuryUnknown statusNCT01802996Phase 4
39Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal CancerUnknown statusNCT00628784Phase 4
40Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous PolyposisUnknown statusNCT02175914Phase 4
41Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsUnknown statusNCT00454376Phase 4
42Comparison the Level of CTGF Protein and Related Cytokine in Pleural EffusionUnknown statusNCT00313066Phase 4
43The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's DiseaseUnknown statusNCT02010762Phase 4
44HIV Persistence and Viral ReservoirsUnknown statusNCT01025427Phase 4
45Prophylaxis of CHB Patients With Malignant Tumor Receiving ChemotherapyUnknown statusNCT02081469Phase 4
46Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic SurgeryUnknown statusNCT01930318Phase 4
47Role of Parecoxib Sodium for Postoperative Pain Management in Open HepatectomyUnknown statusNCT02204878Phase 4
48Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive DiagnosisCompletedNCT01575574Phase 4
49Drug-eluting Bead in Hepatocellular CarcinomaCompletedNCT01332669Phase 4
50Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous ThrombusCompletedNCT01600196Phase 4

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS68/NDF-RT46:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes, PMIDs: 24329789, 19342963, 23904171, 21498393, 22996367, 19304471, 22555974, 15800326, 23650429, 21325070, 24218514, 8170938, 12242449


Cochrane evidence based reviews: liver neoplasms

Genetic Tests for Hepatocellular Carcinoma

About this section

Genetic tests related to Hepatocellular Carcinoma:

id Genetic test Affiliating Genes
1 Hepatocellular Carcinoma27
2 Neoplasm of the Liver27

Anatomical Context for Hepatocellular Carcinoma

About this section

MalaCards organs/tissues related to Hepatocellular Carcinoma:

36
Liver, Endothelial, T cells, Testes, Skin, Colon, Thyroid

Publications for Hepatocellular Carcinoma

About this section

Articles related to Hepatocellular Carcinoma:

(show top 50)    (show all 9218)
idTitleAuthorsYear
1
WNT1 Gene from WNT Signaling Pathway Is a Direct Target of miR-122 in Hepatocellular Carcinoma. (27687586)
2017
2
Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma. (28530649)
2017
3
Oncogenic function of Plac1 on the proliferation and metastasis in hepatocellular carcinoma cells. (27878289)
2017
4
NEK2 serves as a prognostic biomarker for hepatocellular carcinoma. (28101574)
2017
5
Overexpression of NAD(P)H: Quinone Oxidoreductase 1 Inhibits Hepatocellular Carcinoma Cell Proliferation and Induced Apoptosis by Activating AMPK/PGC-1I+ Pathway. (28191864)
2017
6
Histological Subtypes of Hepatocellular Carcinoma Are Related To Gene Mutations and Molecular Tumour Classification. (28532995)
2017
7
A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma. (28529568)
2017
8
Modification of p27 with O-linked N-acetylglucosamine regulates cell proliferation in hepatocellular carcinoma. (27175940)
2017
9
Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma. (28052155)
2017
10
Diabetes mellitus increases the risk of intrahepatic recurrence of hepatocellular carcinoma after surgical resection. (28085178)
2017
11
Integrin I^4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma. (28084395)
2017
12
Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells. (28339084)
2017
13
Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma. (28042245)
2017
14
miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma. (28529562)
2017
15
Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. (28085184)
2017
16
CKLF-Like MARVEL Transmembrane Domain-Containing Member 3 (CMTM3) Inhibits the Proliferation and Tumorigenisis in Hepatocellular Carcinoma Cells. (27629543)
2017
17
Increased ERp57 Expression in HBV-Related Hepatocellular Carcinoma: Possible Correlation and Prognosis. (28373975)
2017
18
High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway. (28347229)
2017
19
Klf4 inhibits tumor growth and metastasis by targeting microRNA-31 in human hepatocellular carcinoma. (27909734)
2017
20
Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy. (28085695)
2017
21
Long non-coding RNA XIST promotes cell growth by regulating miR-139-5p/PDK1/AKT axis in hepatocellular carcinoma. (28231734)
2017
22
Isorhynchophylline, a Potent Plant Alkaloid, Induces Apoptotic and Anti-Metastatic Effects in Human Hepatocellular Carcinoma Cells through the Modulation of Diverse Cell Signaling Cascades. (28534824)
2017
23
Association of Inflammasome Components in Background Liver with Poor Prognosis After Curatively-resected Hepatocellular Carcinoma. (28011505)
2017
24
B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells. (28351336)
2017
25
Hepatocellular carcinoma presenting with Budd-Chiari syndrome, right atrial thrombus and pulmonary emboli. (28372458)
2017
26
Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma. (28205209)
2017
27
Effect of Age (over 75A Years) on Postoperative Complications and Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. (28083840)
2017
28
Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. (28079796)
2017
29
Resin versus Glass Microspheres for Yttrium-90 Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma using Pretreatment Partition Model Dosimetry. (28082436)
2017
30
SIRT3 functions as a tumor suppressor in hepatocellular carcinoma. (28347248)
2017
31
Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline. (28422868)
2017
32
MicroRNA-200a Suppresses Cell Invasion and Migration by Directly Targeting GAB1 in Hepatocellular Carcinoma. (28081727)
2017
33
Synergisic effect of APRIL knockdown and Jiedu Xiaozheng Yin, a Chinese medicinal recipe, on the inhibition of hepatocellular carcinoma cell proliferation. (28035399)
2017
34
Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens. (28532743)
2017
35
Hepatocellular Carcinoma in Fanconi-Bickel Syndrome. (28382841)
2017
36
Long non-coding RNA colon cancer-associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression. (28381168)
2017
37
MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression. (27704267)
2017
38
The Significance of Glypican-3 Expression Profiling in the Tumor Cellular Origin Theoretical System for Hepatocellular Carcinoma Progression. (28087980)
2017
39
Stratified aspartate aminotransferase-to-platelet ratio index accurately predicts survival in hepatocellular carcinoma patients undergoing curative liver resection. (28351330)
2017
40
The Expression and Functional Significance of Runx2 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry and Epithelial-Mesenchymal Transition. (28264434)
2017
41
A 4-Phenoxyphenol Derivative Exerts Inhibitory Effects on Human Hepatocellular Carcinoma Cells through Regulating Autophagy and Apoptosis Accompanied by Downregulating I+-Tubulin Expression. (28531143)
2017
42
Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. (28533669)
2017
43
Targeting MUC1 and JNK by RNA interference and inhibitor inhibit the development of hepatocellular carcinoma. (28012230)
2017
44
What is the optimal treatment of metastatic hepatocellular carcinoma after complete resection; case presentation of ovarian metastasis. (28534387)
2017
45
CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis. (28386553)
2017
46
Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma. (28533668)
2017
47
Overexpression of RIP140 suppresses the malignant potential of hepatocellular carcinoma by inhibiting NFa89I_Ba89mediated alternative polarization of macrophages. (28393222)
2017
48
Bioinformatics prediction and experimental validation of microRNA-20a targeting Cyclin D1 in hepatocellular carcinoma. (28378640)
2017
49
Polyethylene glycol-poly(I/-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma. (28533682)
2017
50
Human U Three Protein 14a Expression is Increased in Hepatocellular Carcinoma and Associated with Poor Prognosis. (28218222)
2017

Variations for Hepatocellular Carcinoma

About this section

UniProtKB/Swiss-Prot genetic disease variations for Hepatocellular Carcinoma:

70 (show all 21)
id Symbol AA change Variation ID SNP ID
1AXIN1p.Leu106ArgVAR_015589
2AXIN1p.Pro345LeuVAR_015590rs779951904
3AXIN1p.Gly425SerVAR_015591rs116350678
4AXIN1p.Gly650SerVAR_015592rs117208012
5CDKN3p.Trp31ArgVAR_013842
6CDKN3p.Phe78LeuVAR_013843
7CDKN3p.Cys79TyrVAR_013844
8CDKN3p.Asn91LysVAR_013845rs760687800
9CDKN3p.Asp94ValVAR_013846
10CDKN3p.Leu95PheVAR_013847
11CDKN3p.Ile108ValVAR_013848rs144479038
12CDKN3p.Asn187SerVAR_013849
13CDKN3p.Lys195IleVAR_013850
14METp.Thr1173IleVAR_032490rs121913675
15METp.Lys1244ArgVAR_032492rs121913677
16METp.Met1250IleVAR_032493rs121913676
17MTUS1p.Gln75LysVAR_035173rs61733703
18MTUS1p.Ala563SerVAR_035178
19MTUS1p.Asn873HisVAR_035180rs187103704
20MTUS1p.Gln1201ArgVAR_035184rs567116808
21PIK3CAp.Glu545AlaVAR_026176rs121913274

Clinvar genetic disease variations for Hepatocellular Carcinoma:

5 (show all 234)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_ 000546.5(TP53): c.742C> T (p.Arg248Trp)SNVPathogenic/ Likely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
2TP53NM_ 000546.5(TP53): c.733G> T (p.Gly245Cys)SNVPathogenic/ Likely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
3TP53NM_ 000546.5(TP53): c.469G> T (p.Val157Phe)SNVPathogenicrs121912654GRCh37Chr 17, 7578461: 7578461
4TP53NM_ 000546.5(TP53): c.725G> A (p.Cys242Tyr)SNVPathogenic/ Likely pathogenicrs121912655GRCh37Chr 17, 7577556: 7577556
5TP53NM_ 000546.5(TP53): c.734G> A (p.Gly245Asp)SNVPathogenic/ Likely pathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
6TP53NM_ 000546.5(TP53): c.743G> A (p.Arg248Gln)SNVPathogenic/ Likely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
7TP53NM_ 000546.5(TP53): c.722C> T (p.Ser241Phe)SNVPathogenic/ Likely pathogenicrs28934573GRCh37Chr 17, 7577559: 7577559
8TP53NM_ 000546.5(TP53): c.733G> A (p.Gly245Ser)SNVPathogenic/ Likely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
9TP53NM_ 000546.5(TP53): c.818G> A (p.Arg273His)SNVPathogenic/ Likely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
10TP53NM_ 000546.5(TP53): c.451C> A (p.Pro151Thr)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
11TP53NM_ 000546.5(TP53): c.451C> T (p.Pro151Ser)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
12TP53NM_ 000546.5(TP53): c.659A> C (p.Tyr220Ser)SNVPathogenic/ Likely pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
13HRASNM_ 005343.3(HRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
14HRASNM_ 005343.3(HRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs104894230GRCh37Chr 11, 534288: 534288
15HRASNM_ 005343.3(HRAS): c.37G> T (p.Gly13Cys)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
16HRASNM_ 005343.3(HRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
17TP53NM_ 000546.5(TP53): c.488A> G (p.Tyr163Cys)SNVPathogenic/ Likely pathogenicrs148924904GRCh37Chr 17, 7578442: 7578442
18TP53NM_ 000546.5(TP53): c.535C> T (p.His179Tyr)SNVPathogenic/ Likely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
19TP53NM_ 000546.5(TP53): c.580C> T (p.Leu194Phe)SNVPathogenic/ Likely pathogenicrs587780071GRCh37Chr 17, 7578269: 7578269
20TP53NM_ 000546.5(TP53): c.659A> G (p.Tyr220Cys)SNVPathogenic/ Likely pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
21TP53NM_ 000546.5(TP53): c.701A> G (p.Tyr234Cys)SNVPathogenic/ Likely pathogenicrs587780073GRCh37Chr 17, 7577580: 7577580
22TP53NM_ 000546.5(TP53): c.638G> A (p.Arg213Gln)SNVPathogenic/ Likely pathogenicrs587778720GRCh38Chr 17, 7674893: 7674893
23PIK3CANM_ 006218.3(PIK3CA): c.3140A> G (p.His1047Arg)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
24PIK3CANM_ 006218.3(PIK3CA): c.3140A> T (p.His1047Leu)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
25PIK3CANM_ 006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
26PIK3CANM_ 006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)SNVPathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
27PIK3CANM_ 006218.3(PIK3CA): c.3203dupA (p.Asn1068Lysfs)duplicationPathogenicrs587776802GRCh37Chr 3, 178952148: 178952148
28NRASNM_ 002524.4(NRAS): c.182A> G (p.Gln61Arg)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
29AKT1NM_ 005163.2(AKT1): c.49G> A (p.Glu17Lys)SNVPathogenic/ Likely pathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
30TP53NM_ 000546.5(TP53): c.844C> G (p.Arg282Gly)SNVPathogenic/ Likely pathogenicrs28934574GRCh37Chr 17, 7577094: 7577094
31TP53NM_ 000546.5(TP53): c.842A> G (p.Asp281Gly)SNVPathogenic/ Likely pathogenicrs587781525GRCh37Chr 17, 7577096: 7577096
32TP53NM_ 000546.5(TP53): c.404G> A (p.Cys135Tyr)SNVLikely pathogenicrs587781991GRCh37Chr 17, 7578526: 7578526
33IGF2RNM_ 000876.3(IGF2R): c.4346G> T (p.Gly1449Val)SNVPathogenicrs121434587GRCh37Chr 6, 160490993: 160490993
34IGF2RNM_ 000876.3(IGF2R): c.4391G> A (p.Gly1464Glu)SNVPathogenicrs121434588GRCh37Chr 6, 160491038: 160491038
35IDH1NM_ 001282386.1(IDH1): c.395G> A (p.Arg132His)SNVPathogenic/ Likely pathogenicrs121913500GRCh38Chr 2, 208248388: 208248388
36PIK3CANM_ 006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)SNV, HaplotypePathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
37GNASNM_ 000516.5(GNAS): c.601C> T (p.Arg201Cys)SNVPathogenic/ Likely pathogenicrs11554273GRCh37Chr 20, 57484420: 57484420
38GNASNM_ 000516.5(GNAS): c.602G> A (p.Arg201His)SNVPathogenic/ Likely pathogenicrs121913495GRCh37Chr 20, 57484421: 57484421
39CTNNB1NM_ 001904.3(CTNNB1): c.98C> A (p.Ser33Tyr)SNVPathogenic/ Likely pathogenicrs121913400GRCh37Chr 3, 41266101: 41266101
40CTNNB1NM_ 001904.3(CTNNB1): c.95A> G (p.Asp32Gly)SNVPathogenic/ Likely pathogenicrs121913396GRCh37Chr 3, 41266098: 41266098
41CTNNB1NM_ 001904.3(CTNNB1): c.110C> G (p.Ser37Cys)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
42CTNNB1NM_ 001904.3(CTNNB1): c.94G> T (p.Asp32Tyr)SNVPathogenic/ Likely pathogenicrs28931588GRCh37Chr 3, 41266097: 41266097
43CTNNB1NM_ 001904.3(CTNNB1): c.98C> T (p.Ser33Phe)SNVPathogenic/ Likely pathogenicrs121913400GRCh37Chr 3, 41266101: 41266101
44CTNNB1NM_ 001904.3(CTNNB1): c.101G> A (p.Gly34Glu)SNVPathogenic/ Likely pathogenicrs28931589GRCh37Chr 3, 41266104: 41266104
45CTNNB1NM_ 001904.3(CTNNB1): c.110C> T (p.Ser37Phe)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
46CTNNB1NM_ 001904.3(CTNNB1): c.122C> T (p.Thr41Ile)SNVPathogenic/ Likely pathogenicrs121913413GRCh37Chr 3, 41266125: 41266125
47CTNNB1NM_ 001904.3(CTNNB1): c.134C> T (p.Ser45Phe)SNVPathogenic/ Likely pathogenicrs121913409GRCh37Chr 3, 41266137: 41266137
48CTNNB1NM_ 001904.3(CTNNB1): c.133T> C (p.Ser45Pro)SNVPathogenic/ Likely pathogenicrs121913407GRCh37Chr 3, 41266136: 41266136
49HRASNM_ 005343.3(HRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs104894226GRCh38Chr 11, 534285: 534285
50TP53NM_ 000546.5(TP53): c.842A> T (p.Asp281Val)SNVPathogenic/ Likely pathogenicrs587781525GRCh38Chr 17, 7673778: 7673778
51TP53NM_ 000546.5(TP53): c.856G> A (p.Glu286Lys)SNVPathogenic/ Likely pathogenicrs786201059GRCh37Chr 17, 7577082: 7577082
52TP53NM_ 000546.5(TP53): c.578A> T (p.His193Leu)SNVLikely pathogenicrs786201838GRCh37Chr 17, 7578271: 7578271
53TP53NM_ 000546.5(TP53): c.487T> G (p.Tyr163Asp)SNVLikely pathogenicrs786203436GRCh37Chr 17, 7578443: 7578443
54GNASNM_ 000516.5(GNAS): c.602G> T (p.Arg201Leu)SNVPathogenic/ Likely pathogenicrs121913495GRCh37Chr 20, 57484421: 57484421
55TP53NM_ 000546.5(TP53): c.824G> A (p.Cys275Tyr)SNVPathogenic/ Likely pathogenicrs863224451GRCh38Chr 17, 7673796: 7673796
56TP53NM_ 000546.5(TP53): c.584T> C (p.Ile195Thr)SNVPathogenic/ Likely pathogenicrs760043106GRCh38Chr 17, 7674947: 7674947
57PIK3CANM_ 006218.3(PIK3CA): c.1635G> T (p.Glu545Asp)SNVPathogenic/ Likely pathogenicrs121913275GRCh37Chr 3, 178936093: 178936093
58FGFR1NM_ 023110.2(FGFR1): c.1966A> G (p.Lys656Glu)SNVPathogenic/ Likely pathogenicrs869320694GRCh37Chr 8, 38272308: 38272308
59TP53NM_ 000546.5(TP53): c.743G> T (p.Arg248Leu)SNVLikely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
60TP53NM_ 000546.5(TP53): c.577C> T (p.His193Tyr)SNVLikely pathogenicrs876658468GRCh37Chr 17, 7578272: 7578272
61TP53NM_ 000546.5(TP53): c.818G> C (p.Arg273Pro)SNVLikely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
62TP53NM_ 000546.5(TP53): c.638G> C (p.Arg213Pro)SNVLikely pathogenicrs587778720GRCh37Chr 17, 7578211: 7578211
63TP53NM_ 000546.5(TP53): c.715A> G (p.Asn239Asp)SNVLikely pathogenicrs876660807GRCh37Chr 17, 7577566: 7577566
64TP53NM_ 000546.5(TP53): c.743G> C (p.Arg248Pro)SNVLikely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
65TP53NM_ 000546.5(TP53): c.643A> G (p.Ser215Gly)SNVLikely pathogenicrs886039484GRCh37Chr 17, 7578206: 7578206
66TP53NM_ 000546.5(TP53): c.734G> C (p.Gly245Ala)SNVLikely pathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
67NRASNM_ 002524.4(NRAS): c.182A> C (p.Gln61Pro)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
68PIK3CANM_ 006218.3(PIK3CA): c.1624G> A (p.Glu542Lys)SNVPathogenic/ Likely pathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
69HRASNM_ 005343.3(HRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
70TP53NM_ 000546.5(TP53): c.731G> A (p.Gly244Asp)SNVLikely pathogenicrs985033810GRCh37Chr 17, 7577550: 7577550
71NRASNM_ 002524.4(NRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs121913255GRCh37Chr 1, 115256528: 115256528
72NRASNM_ 002524.4(NRAS): c.182A> T (p.Gln61Leu)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
73IDH1NM_ 005896.3(IDH1): c.395G> T (p.Arg132Leu)SNVPathogenic/ Likely pathogenicrs121913500GRCh37Chr 2, 209113112: 209113112
74IDH1NM_ 001282387.1(IDH1): c.394C> T (p.Arg132Cys)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
75IDH1NM_ 001282387.1(IDH1): c.394C> G (p.Arg132Gly)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
76IDH1NM_ 001282387.1(IDH1): c.394C> A (p.Arg132Ser)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
77CTNNB1NM_ 001904.3(CTNNB1): c.110C> A (p.Ser37Tyr)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
78CTNNB1NM_ 001904.3(CTNNB1): c.134C> A (p.Ser45Tyr)SNVPathogenic/ Likely pathogenicrs121913409GRCh37Chr 3, 41266137: 41266137
79PIK3CANM_ 006218.3(PIK3CA): c.1633G> C (p.Glu545Gln)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
80KRASNM_ 004985.4(KRAS): c.351A> C (p.Lys117Asn)SNVPathogenic/ Likely pathogenicrs770248150GRCh37Chr 12, 25378647: 25378647
81IDH2NM_ 001289910.1(IDH2): c.359G> T (p.Arg120Met)SNVPathogenic/ Likely pathogenicrs121913503GRCh37Chr 15, 90631838: 90631838
82IDH2NM_ 001289910.1(IDH2): c.359G> A (p.Arg120Lys)SNVPathogenic/ Likely pathogenicrs121913503GRCh37Chr 15, 90631838: 90631838
83SF3B1NM_ 012433.3(SF3B1): c.1996A> G (p.Lys666Glu)SNVLikely pathogenicrs754688962GRCh37Chr 2, 198267361: 198267361
84TP53NM_ 001126112.2(TP53): c.746G> C (p.Arg249Thr)SNVLikely pathogenicrs587782329GRCh37Chr 17, 7577535: 7577535
85TP53NM_ 001126112.2(TP53): c.518T> G (p.Val173Gly)SNVLikely pathogenicrs1057519747GRCh37Chr 17, 7578412: 7578412
86TP53NM_ 001126113.2(TP53): c.518T> C (p.Val173Ala)SNVLikely pathogenicrs1057519747GRCh37Chr 17, 7578412: 7578412
87HRAS; LRRC56NM_ 005343.3(HRAS): c.182A> T (p.Gln61Leu)SNVLikely pathogenicrs121913233GRCh37Chr 11, 533874: 533874
88CTNNB1NM_ 001904.3(CTNNB1): c.94G> C (p.Asp32His)SNVLikely pathogenicrs28931588GRCh37Chr 3, 41266097: 41266097
89CTNNB1NM_ 001904.3(CTNNB1): c.94G> A (p.Asp32Asn)SNVLikely pathogenicrs28931588GRCh37Chr 3, 41266097: 41266097
90CTNNB1NM_ 001904.3(CTNNB1): c.95A> C (p.Asp32Ala)SNVLikely pathogenicrs121913396GRCh37Chr 3, 41266098: 41266098
91CTNNB1NM_ 001904.3(CTNNB1): c.95A> T (p.Asp32Val)SNVLikely pathogenicrs121913396GRCh37Chr 3, 41266098: 41266098
92CTNNB1NM_ 001904.3(CTNNB1): c.98C> G (p.Ser33Cys)SNVLikely pathogenicrs121913400GRCh37Chr 3, 41266101: 41266101
93CTNNB1NM_ 001904.3(CTNNB1): c.100G> C (p.Gly34Arg)SNVLikely pathogenicrs121913399GRCh37Chr 3, 41266103: 41266103
94CTNNB1NM_ 001904.3(CTNNB1): c.109T> C (p.Ser37Pro)SNVLikely pathogenicrs121913228GRCh37Chr 3, 41266112: 41266112
95CTNNB1NM_ 001904.3(CTNNB1): c.109T> G (p.Ser37Ala)SNVLikely pathogenicrs121913228GRCh37Chr 3, 41266112: 41266112
96CTNNB1NM_ 001904.3(CTNNB1): c.134C> G (p.Ser45Cys)SNVLikely pathogenicrs121913409GRCh37Chr 3, 41266137: 41266137
97PIK3CANM_ 006218.3(PIK3CA): c.1624G> C (p.Glu542Gln)SNVLikely pathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
98CDKN2ANM_ 058195.3(CDKN2A): c.290C> T (p.Ala97Val)SNVLikely pathogenicrs121913385GRCh37Chr 9, 21971111: 21971111
99HRAS; LRRC56NM_ 005343.3(HRAS): c.182A> C (p.Gln61Pro)SNVLikely pathogenicrs121913233GRCh37Chr 11, 533874: 533874
100CDKN2ANM_ 058195.3(CDKN2A): c.291A> G (p.Ala97=)SNVLikely pathogenicrs1057519881GRCh38Chr 9, 21971111: 21971111
101CDKN2ANM_ 058195.3(CDKN2A): c.290C> G (p.Ala97Gly)SNVLikely pathogenicrs121913385GRCh37Chr 9, 21971111: 21971111
102CDKN2ANM_ 000077.4(CDKN2A): c.249C> G (p.His83Gln)SNVLikely pathogenicrs34968276GRCh37Chr 9, 21971109: 21971109
103CREBBPNM_ 004380.2(CREBBP): c.4337G> T (p.Arg1446Leu)SNVLikely pathogenicrs1057519884GRCh37Chr 16, 3788617: 3788617
104CREBBPNM_ 004380.2(CREBBP): c.4337G> A (p.Arg1446His)SNVLikely pathogenicrs1057519884GRCh37Chr 16, 3788617: 3788617
105CREBBPNM_ 004380.2(CREBBP): c.4336C> G (p.Arg1446Gly)SNVLikely pathogenicrs398124146GRCh37Chr 16, 3788618: 3788618
106CTNNB1NM_ 001904.3(CTNNB1): c.101G> C (p.Gly34Ala)SNVLikely pathogenicrs28931589GRCh37Chr 3, 41266104: 41266104
107CTNNB1NM_ 001904.3(CTNNB1): c.97T> C (p.Ser33Pro)SNVLikely pathogenicrs1057519886GRCh37Chr 3, 41266100: 41266100
108CTNNB1NM_ 001904.3(CTNNB1): c.97T> G (p.Ser33Ala)SNVLikely pathogenicrs1057519886GRCh37Chr 3, 41266100: 41266100
109CTNNB1NM_ 001904.3(CTNNB1): c.97T> A (p.Ser33Thr)SNVLikely pathogenicrs1057519886GRCh37Chr 3, 41266100: 41266100
110CTNNB1NM_ 001904.3(CTNNB1): c.122C> A (p.Thr41Asn)SNVLikely pathogenicrs121913413GRCh38Chr 3, 41224634: 41224634
111FGFR1NM_ 023110.2(FGFR1): c.1968G> C (p.Lys656Asn)SNVLikely pathogenicrs1057519897GRCh37Chr 8, 38272306: 38272306
112IDH2NM_ 001289910.1(IDH2): c.358A> T (p.Arg120Trp)SNVLikely pathogenicrs1057519906GRCh37Chr 15, 90631839: 90631839
113IDH2NM_ 001289910.1(IDH2): c.358A> G (p.Arg120Gly)SNVLikely pathogenicrs1057519906GRCh37Chr 15, 90631839: 90631839
114HRAS; LRRC56NM_ 005343.3(HRAS): c.38G> C (p.Gly13Ala)SNVLikely pathogenicrs104894226GRCh37Chr 11, 534285: 534285
115HRAS; LRRC56NM_ 005343.3(HRAS): c.181C> G (p.Gln61Glu)SNVLikely pathogenicrs28933406GRCh38Chr 11, 533875: 533875
116NFE2L2NM_ 001145413.3(NFE2L2): c.187G> C (p.Glu63Gln)SNVLikely pathogenicrs1057519922GRCh37Chr 2, 178098810: 178098810
117NFE2L2NM_ 001313904.1(NFE2L2): c.6G> A (p.Lys2=)SNVLikely pathogenicrs1057519922GRCh37Chr 2, 178098810: 178098810
118NFE2L2NM_ 001145413.3(NFE2L2): c.188A> T (p.Glu63Val)SNVLikely pathogenicrs1057519923GRCh37Chr 2, 178098809: 178098809
119NFE2L2NM_ 001313902.1(NFE2L2): c.237G> T (p.Glu79Asp)SNVLikely pathogenicrs1057519924GRCh37Chr 2, 178098808: 178098808
120PIK3CANM_ 006218.3(PIK3CA): c.1357G> A (p.Glu453Lys)SNVLikely pathogenicrs1057519925GRCh37Chr 3, 178928079: 178928079
121PIK3CANM_ 006218.3(PIK3CA): c.1357G> C (p.Glu453Gln)SNVLikely pathogenicrs1057519925GRCh37Chr 3, 178928079: 178928079
122PIK3CANM_ 006218.3(PIK3CA): c.1359A> T (p.Glu453Asp)SNVLikely pathogenicrs1057519926GRCh37Chr 3, 178928081: 178928081
123PIK3CANM_ 006218.3(PIK3CA): c.1625A> C (p.Glu542Ala)SNVLikely pathogenicrs1057519927GRCh37Chr 3, 178936083: 178936083
124PIK3CANM_ 006218.3(PIK3CA): c.1625A> T (p.Glu542Val)SNVLikely pathogenicrs1057519927GRCh37Chr 3, 178936083: 178936083
125PIK3CANM_ 006218.3(PIK3CA): c.1625A> G (p.Glu542Gly)SNVLikely pathogenicrs1057519927GRCh37Chr 3, 178936083: 178936083
126PIK3CANM_ 006218.3(PIK3CA): c.3141T> G (p.His1047Gln)SNVLikely pathogenicrs1057519932GRCh37Chr 3, 178952086: 178952086
127CNOT9NM_ 001271635.1(CNOT9): c.259T> C (p.Ser87Pro)SNVLikely pathogenicrs1057519956GRCh37Chr 2, 219447748: 219447748
128CNOT9NM_ 001271634.1(CNOT9): c.260C> G (p.Ser87Cys)SNVLikely pathogenicrs1057519957GRCh37Chr 2, 219447749: 219447749
129RXRANM_ 001291921.1(RXRA): c.989C> T (p.Ser330Phe)SNVLikely pathogenicrs1057519958GRCh37Chr 9, 137328351: 137328351
130RXRANM_ 001291921.1(RXRA): c.989C> A (p.Ser330Tyr)SNVLikely pathogenicrs1057519958GRCh37Chr 9, 137328351: 137328351
131SF3B2NM_ 006842.2(SF3B2): c.1997A> C (p.His666Pro)SNVLikely pathogenicrs1057519959GRCh37Chr 11, 65830499: 65830499
132SF3B1NM_ 012433.3(SF3B1): c.1996A> C (p.Lys666Gln)SNVLikely pathogenicrs754688962GRCh37Chr 2, 198267361: 198267361
133TP53NM_ 001126113.2(TP53): c.404G> T (p.Cys135Phe)SNVLikely pathogenicrs587781991GRCh37Chr 17, 7578526: 7578526
134TP53NM_ 001126116.1(TP53): c.7T> C (p.Cys3Arg)SNVLikely pathogenicrs1057519975GRCh37Chr 17, 7578527: 7578527
135TP53NM_ 001126118.1(TP53): c.286T> A (p.Cys96Ser)SNVLikely pathogenicrs1057519975GRCh37Chr 17, 7578527: 7578527
136TP53NM_ 001126113.2(TP53): c.403T> G (p.Cys135Gly)SNVLikely pathogenicrs1057519975GRCh37Chr 17, 7578527: 7578527
137TP53NM_ 001126114.2(TP53): c.527G> T (p.Cys176Phe)SNVLikely pathogenicrs786202962GRCh37Chr 17, 7578403: 7578403
138TP53NM_ 001126117.1(TP53): c.130T> A (p.Cys44Ser)SNVLikely pathogenicrs967461896GRCh37Chr 17, 7578404: 7578404
139TP53NM_ 001126117.1(TP53): c.130T> G (p.Cys44Gly)SNVLikely pathogenicrs967461896GRCh37Chr 17, 7578404: 7578404
140TP53NM_ 001126112.2(TP53): c.528C> G (p.Cys176Trp)SNVLikely pathogenicrs1057519980GRCh37Chr 17, 7578402: 7578402
141TP53NM_ 001126117.1(TP53): c.130T> C (p.Cys44Arg)SNVLikely pathogenicrs967461896GRCh37Chr 17, 7578404: 7578404
142TP53NM_ 000546.5(TP53): c.713G> T (p.Cys238Phe)SNVPathogenic/ Likely pathogenicrs730882005GRCh37Chr 17, 7577568: 7577568
143TP53NM_ 000546.5(TP53): c.713G> C (p.Cys238Ser)SNVLikely pathogenicrs730882005GRCh37Chr 17, 7577568: 7577568
144TP53NM_ 001126117.1(TP53): c.316T> C (p.Cys106Arg)SNVLikely pathogenicrs1057519981GRCh37Chr 17, 7577569: 7577569
145TP53NM_ 001126115.1(TP53): c.316T> G (p.Cys106Gly)SNVLikely pathogenicrs1057519981GRCh37Chr 17, 7577569: 7577569
146TP53NM_ 001126113.2(TP53): c.725G> T (p.Cys242Phe)SNVLikely pathogenicrs121912655GRCh37Chr 17, 7577556: 7577556
147TP53NM_ 001126115.1(TP53): c.328T> A (p.Cys110Ser)SNVLikely pathogenicrs1057519982GRCh37Chr 17, 7577557: 7577557
148TP53NM_ 001126116.1(TP53): c.330C> G (p.Cys110Trp)SNVLikely pathogenicrs375874539GRCh37Chr 17, 7577555: 7577555
149TP53NM_ 001126117.1(TP53): c.428G> T (p.Cys143Phe)SNVLikely pathogenicrs863224451GRCh37Chr 17, 7577114: 7577114
150TP53NM_ 001126112.2(TP53): c.824G> C (p.Cys275Ser)SNVLikely pathogenicrs863224451GRCh37Chr 17, 7577114: 7577114
151TP53NM_ 001126112.2(TP53): c.823T> C (p.Cys275Arg)SNVLikely pathogenicrs1057519983GRCh37Chr 17, 7577115: 7577115
152TP53NM_ 001126116.1(TP53): c.445G> T (p.Asp149Tyr)SNVLikely pathogenicrs764146326GRCh37Chr 17, 7577097: 7577097
153TP53NM_ 001126116.1(TP53): c.445G> A (p.Asp149Asn)SNVLikely pathogenicrs764146326GRCh37Chr 17, 7577097: 7577097
154TP53NM_ 001126117.1(TP53): c.447C> G (p.Asp149Glu)SNVLikely pathogenicrs1057519984GRCh37Chr 17, 7577095: 7577095
155TP53NM_ 001126115.1(TP53): c.445G> C (p.Asp149His)SNVLikely pathogenicrs764146326GRCh37Chr 17, 7577097: 7577097
156TP53NM_ 001126117.1(TP53): c.446A> C (p.Asp149Ala)SNVLikely pathogenicrs587781525GRCh37Chr 17, 7577096: 7577096
157TP53NM_ 001126113.2(TP53): c.857A> G (p.Glu286Gly)SNVLikely pathogenicrs1057519985GRCh37Chr 17, 7577081: 7577081
158TP53NM_ 001126117.1(TP53): c.460G> C (p.Glu154Gln)SNVLikely pathogenicrs786201059GRCh37Chr 17, 7577082: 7577082
159TP53NM_ 001126117.1(TP53): c.461A> T (p.Glu154Val)SNVLikely pathogenicrs1057519985GRCh37Chr 17, 7577081: 7577081
160TP53NM_ 000546.5(TP53): c.857A> C (p.Glu286Ala)SNVLikely pathogenicrs1057519985GRCh37Chr 17, 7577081: 7577081
161TP53NM_ 001126113.2(TP53): c.730G> T (p.Gly244Cys)SNVLikely pathogenicrs1057519989GRCh37Chr 17, 7577551: 7577551
162TP53NM_ 001126116.1(TP53): c.334G> A (p.Gly112Ser)SNVLikely pathogenicrs1057519989GRCh37Chr 17, 7577551: 7577551
163TP53NM_ 001126118.1(TP53): c.614G> T (p.Gly205Val)SNVLikely pathogenicrs985033810GRCh37Chr 17, 7577550: 7577550
164TP53NM_ 001126115.1(TP53): c.334G> C (p.Gly112Arg)SNVLikely pathogenicrs1057519989GRCh37Chr 17, 7577551: 7577551
165TP53NM_ 000546.5(TP53): c.734G> T (p.Gly245Val)SNVLikely pathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
166TP53NM_ 001126116.1(TP53): c.337G> C (p.Gly113Arg)SNVLikely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
167TP53NM_ 001126115.1(TP53): c.400G> C (p.Gly134Arg)SNVLikely pathogenicrs1057519990GRCh37Chr 17, 7577142: 7577142
168TP53NM_ 001126113.2(TP53): c.536A> G (p.His179Arg)SNVLikely pathogenicrs1057519991GRCh37Chr 17, 7578394: 7578394
169TP53NM_ 001126117.1(TP53): c.141T> G (p.His47Gln)SNVLikely pathogenicrs876660821GRCh37Chr 17, 7578393: 7578393
170TP53NM_ 001126118.1(TP53): c.419A> T (p.His140Leu)SNVLikely pathogenicrs1057519991GRCh37Chr 17, 7578394: 7578394
171TP53NM_ 001126118.1(TP53): c.418C> A (p.His140Asn)SNVLikely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
172TP53NM_ 001126118.1(TP53): c.418C> G (p.His140Asp)SNVLikely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
173TP53NM_ 001126117.1(TP53): c.140A> C (p.His47Pro)SNVLikely pathogenicrs1057519991GRCh37Chr 17, 7578394: 7578394
174TP53NM_ 001126115.1(TP53): c.182A> C (p.His61Pro)SNVLikely pathogenicrs786201838GRCh37Chr 17, 7578271: 7578271
175TP53NM_ 000546.5(TP53): c.577C> G (p.His193Asp)SNVLikely pathogenicrs876658468GRCh37Chr 17, 7578272: 7578272
176TP53NM_ 001126113.2(TP53): c.577C> A (p.His193Asn)SNVLikely pathogenicrs876658468GRCh37Chr 17, 7578272: 7578272
177TP53NM_ 000546.5(TP53): c.641A> T (p.His214Leu)SNVLikely pathogenicrs1057519992GRCh37Chr 17, 7578208: 7578208
178TP53NM_ 001126115.1(TP53): c.187A> T (p.Ile63Phe)SNVLikely pathogenicrs942158624GRCh37Chr 17, 7578266: 7578266
179TP53NM_ 001126118.1(TP53): c.467T> A (p.Ile156Asn)SNVLikely pathogenicrs760043106GRCh37Chr 17, 7578265: 7578265
180TP53NM_ 001126116.1(TP53): c.188T> G (p.Ile63Ser)SNVLikely pathogenicrs760043106GRCh37Chr 17, 7578265: 7578265
181TP53NM_ 001126116.1(TP53): c.189C> G (p.Ile63Met)SNVLikely pathogenicrs1057519994GRCh37Chr 17, 7578264: 7578264
182TP53NM_ 001126112.2(TP53): c.332T> G (p.Leu111Arg)SNVLikely pathogenicrs1057519997GRCh37Chr 17, 7579355: 7579355
183TP53NM_ 001126113.2(TP53): c.332T> A (p.Leu111Gln)SNVLikely pathogenicrs1057519997GRCh37Chr 17, 7579355: 7579355
184TP53NM_ 000546.5(TP53): c.581T> G (p.Leu194Arg)SNVLikely pathogenicrs1057519998GRCh37Chr 17, 7578268: 7578268
185TP53NM_ 001126113.2(TP53): c.581T> A (p.Leu194His)SNVLikely pathogenicrs1057519998GRCh37Chr 17, 7578268: 7578268
186TP53NM_ 000546.5(TP53): c.581T> C (p.Leu194Pro)SNVLikely pathogenicrs1057519998GRCh37Chr 17, 7578268: 7578268
187TP53NM_ 001126115.1(TP53): c.320A> G (p.Asn107Ser)SNVLikely pathogenicrs1057519999GRCh37Chr 17, 7577565: 7577565
188TP53NM_ 001126114.2(TP53): c.716A> C (p.Asn239Thr)SNVLikely pathogenicrs1057519999GRCh37Chr 17, 7577565: 7577565
189TP53NM_ 001126112.2(TP53): c.452C> A (p.Pro151His)SNVLikely pathogenicrs1057520000GRCh37Chr 17, 7578478: 7578478
190TP53NM_ 001126115.1(TP53): c.56C> G (p.Pro19Arg)SNVLikely pathogenicrs1057520000GRCh37Chr 17, 7578478: 7578478
191TP53NM_ 001126112.2(TP53): c.431A> T (p.Gln144Leu)SNVLikely pathogenicrs786203071GRCh37Chr 17, 7578499: 7578499
192TP53NM_ 001126118.1(TP53): c.315G> T (p.Gln105His)SNVLikely pathogenicrs786201419GRCh37Chr 17, 7578498: 7578498
193TP53NM_ 000546.5(TP53): c.523C> G (p.Arg175Gly)SNVPathogenic/ Likely pathogenicrs138729528GRCh37Chr 17, 7578407: 7578407
194TP53NM_ 001126114.2(TP53): c.638G> T (p.Arg213Leu)SNVLikely pathogenicrs587778720GRCh37Chr 17, 7578211: 7578211
195TP53NM_ 001126112.2(TP53): c.637C> G (p.Arg213Gly)SNVLikely pathogenicrs397516436GRCh37Chr 17, 7578212: 7578212
196TP53NM_ 000546.5(TP53): c.742C> G (p.Arg248Gly)SNVLikely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
197TP53NM_ 001126112.2(TP53): c.746G> T (p.Arg249Met)SNVLikely pathogenicrs587782329GRCh37Chr 17, 7577535: 7577535
198TP53NM_ 001126112.2(TP53): c.818G> T (p.Arg273Leu)SNVLikely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
199TP53NM_ 001126112.2(TP53): c.817C> A (p.Arg273Ser)SNVLikely pathogenicrs121913343GRCh37Chr 17, 7577121: 7577121
200TP53NM_ 000546.5(TP53): c.839G> A (p.Arg280Lys)SNVLikely pathogenicrs121912660GRCh37Chr 17, 7577099: 7577099
201TP53NM_ 001126113.2(TP53): c.838A> G (p.Arg280Gly)SNVLikely pathogenicrs753660142GRCh37Chr 17, 7577100: 7577100
202TP53NM_ 001126112.2(TP53): c.845G> C (p.Arg282Pro)SNVLikely pathogenicrs730882008GRCh37Chr 17, 7577093: 7577093
203TP53NM_ 001126115.1(TP53): c.248G> T (p.Ser83Ile)SNVLikely pathogenicrs587782177GRCh37Chr 17, 7578205: 7578205
204TP53NM_ 000546.5(TP53): c.644G> A (p.Ser215Asn)SNVLikely pathogenicrs587782177GRCh37Chr 17, 7578205: 7578205
205TP53NM_ 000546.5(TP53): c.373A> C (p.Thr125Pro)SNVLikely pathogenicrs1057520003GRCh37Chr 17, 7579314: 7579314
206TP53NM_ 001126113.2(TP53): c.374C> G (p.Thr125Arg)SNVLikely pathogenicrs786201057GRCh37Chr 17, 7579313: 7579313
207TP53NM_ 000546.5(TP53): c.517G> T (p.Val173Leu)SNVLikely pathogenicrs876660754GRCh37Chr 17, 7578413: 7578413
208TP53NM_ 001126113.2(TP53): c.518T> A (p.Val173Glu)SNVLikely pathogenicrs1057519747GRCh37Chr 17, 7578412: 7578412
209TP53NM_ 001126116.1(TP53): c.424G> T (p.Val142Phe)SNVLikely pathogenicrs1057520005GRCh37Chr 17, 7577118: 7577118
210TP53NM_ 001126116.1(TP53): c.425T> A (p.Val142Asp)SNVLikely pathogenicrs1057520006GRCh37Chr 17, 7577117: 7577117
211TP53NM_ 001126116.1(TP53): c.425T> G (p.Val142Gly)SNVLikely pathogenicrs1057520006GRCh37Chr 17, 7577117: 7577117
212TP53NM_ 001126113.2(TP53): c.821T> C (p.Val274Ala)SNVLikely pathogenicrs1057520006GRCh37Chr 17, 7577117: 7577117
213TP53NM_ 001126115.1(TP53): c.424G> C (p.Val142Leu)SNVLikely pathogenicrs1057520005GRCh37Chr 17, 7577118: 7577118
214TP53NM_ 001126115.1(TP53): c.91T> A (p.Tyr31Asn)SNVLikely pathogenicrs786203436GRCh37Chr 17, 7578443: 7578443
215TP53NM_ 001126112.2(TP53): c.487T> C (p.Tyr163His)SNVLikely pathogenicrs786203436GRCh37Chr 17, 7578443: 7578443
216TP53NM_ 001126118.1(TP53): c.497A> G (p.Tyr166Cys)SNVLikely pathogenicrs1057520007GRCh37Chr 17, 7578235: 7578235
217TP53NM_ 001126117.1(TP53): c.218A> T (p.Tyr73Phe)SNVLikely pathogenicrs1057520007GRCh37Chr 17, 7578235: 7578235
218TP53NM_ 001126118.1(TP53): c.497A> C (p.Tyr166Ser)SNVLikely pathogenicrs1057520007GRCh37Chr 17, 7578235: 7578235
219TP53NM_ 001126113.2(TP53): c.613T> A (p.Tyr205Asn)SNVLikely pathogenicrs1057520008GRCh37Chr 17, 7578236: 7578236
220TP53NM_ 000546.5(TP53): c.613T> C (p.Tyr205His)SNVLikely pathogenicrs1057520008GRCh37Chr 17, 7578236: 7578236
221TP53NM_ 000546.5(TP53): c.658T> C (p.Tyr220His)SNVLikely pathogenicrs530941076GRCh37Chr 17, 7578191: 7578191
222TP53NM_ 001126118.1(TP53): c.541T> A (p.Tyr181Asn)SNVLikely pathogenicrs530941076GRCh37Chr 17, 7578191: 7578191
223TP53NM_ 000546.5(TP53): c.658T> G (p.Tyr220Asp)SNVLikely pathogenicrs530941076GRCh37Chr 17, 7578191: 7578191
224TP53NM_ 001126114.2(TP53): c.701A> C (p.Tyr234Ser)SNVLikely pathogenicrs587780073GRCh37Chr 17, 7577580: 7577580
225TP53NM_ 001126113.2(TP53): c.700T> C (p.Tyr234His)SNVLikely pathogenicrs864622237GRCh37Chr 17, 7577581: 7577581
226TP53NM_ 000546.5(TP53): c.700T> A (p.Tyr234Asn)SNVLikely pathogenicrs864622237GRCh37Chr 17, 7577581: 7577581
227PIK3CANM_ 006218.3(PIK3CA): c.3139C> T (p.His1047Tyr)SNVPathogenic/ Likely pathogenicrs121913281GRCh37Chr 3, 178952084: 178952084
228KRASNM_ 033360.3(KRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs17851045GRCh37Chr 12, 25380275: 25380275
229PDGFRLPDGRL, 2-BP DELdeletionPathogenic
230AXIN1NM_ 003502.3(AXIN1): c.1085_ 1116del32 (p.Val362Alafs)deletionPathogenicrs587776627GRCh38Chr 16, 309973: 310004
231NRASNM_ 002524.4(NRAS): c.181C> A (p.Gln61Lys)SNVPathogenic/ Likely pathogenicrs121913254GRCh37Chr 1, 115256530: 115256530
232CASP8NM_ 001228.4(CASP8): c.1279_ 1280delGT (p.Val427Phefs)deletionPathogenicrs587776665GRCh37Chr 2, 202149964: 202149965
233APCNM_ 000038.5(APC): c.4183A> T (p.Ser1395Cys)SNVPathogenicrs137854578GRCh37Chr 5, 112175474: 112175474
234APCNM_ 000038.5(APC): c.1695delA (p.Val566Leufs)deletionPathogenicrs397514032GRCh37Chr 5, 112164621: 112164621

Cosmic variations for Hepatocellular Carcinoma:

8 (show top 50)    (show all 569)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM10690TP53liver,NS,carcinoma,hepatocellular carcinomac.473G>Ap.R158H58
2COSM11286TP53liver,NS,carcinoma,hepatocellular carcinomac.1015G>Tp.E339*58
3COSM954CSF1Rliver,NS,carcinoma,hepatocellular carcinomac.902T>Cp.L301S58
4COSM10812TP53liver,NS,carcinoma,hepatocellular carcinomac.722C>Tp.S241F58
5COSM11205TP53liver,NS,carcinoma,hepatocellular carcinomac.796G>Cp.G266R58
6COSM251410RPS6KA3liver,NS,carcinoma,hepatocellular carcinomac.766G>Ap.V256M58
7COSM99221GNASliver,NS,carcinoma,hepatocellular carcinomac.602G>Tp.R201L58
8COSM5676CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.122C>Tp.T41I58
9COSM694METliver,NS,carcinoma,hepatocellular carcinomac.3804G>Ap.M1268I58
10COSM10648TP53liver,NS,carcinoma,hepatocellular carcinomac.524G>Ap.R175H58
11COSM43970TP53liver,NS,carcinoma,hepatocellular carcinomac.380C>Ap.S127Y58
12COSM132988NFE2L2liver,NS,carcinoma,hepatocellular carcinomac.238A>Cp.T80P58
13COSM44026TP53liver,NS,carcinoma,hepatocellular carcinomac.559G>Ap.G187S58
14COSM44203TP53liver,NS,carcinoma,hepatocellular carcinomac.566C>Ap.A189D58
15COSM5691CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.95A>Tp.D32V58
16COSM5664CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.121A>Gp.T41A58
17COSM43833TP53liver,NS,carcinoma,hepatocellular carcinomac.578A>Cp.H193P58
18COSM44424TP53liver,NS,carcinoma,hepatocellular carcinomac.590T>Ap.V197E58
19COSM10750TP53liver,NS,carcinoma,hepatocellular carcinomac.490A>Tp.K164*58
20COSM5669CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.98C>Tp.S33F58
21COSM44227TP53liver,NS,carcinoma,hepatocellular carcinomac.854A>Tp.E285V58
22COSM44794TP53liver,NS,carcinoma,hepatocellular carcinomac.392A>Tp.N131I58
23COSM5685CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.133T>Gp.S45A58
24COSM13400EGFRliver,NS,carcinoma,hepatocellular carcinomac.2457G>Ap.V819V58
25COSM5663CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.133T>Cp.S45P58
26COSM5679CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.110C>Gp.S37C58
27COSM5684CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.100G>Cp.G34R58
28COSM10733TP53liver,NS,carcinoma,hepatocellular carcinomac.574C>Tp.Q192*58
29COSM45045TP53liver,NS,carcinoma,hepatocellular carcinomac.695T>Gp.I232S58
30COSM44393TP53liver,NS,carcinoma,hepatocellular carcinomac.821T>Cp.V274A58
31COSM10905TP53liver,NS,carcinoma,hepatocellular carcinomac.451C>Tp.P151S58
32COSM5677CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.98C>Gp.S33C58
33COSM10958TP53liver,NS,carcinoma,hepatocellular carcinomac.797G>Tp.G266V58
34COSM520KRASliver,NS,carcinoma,hepatocellular carcinomac.35G>Tp.G12V58
35COSM5678CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.107A>Cp.H36P58
36COSM10667TP53liver,NS,carcinoma,hepatocellular carcinomac.646G>Ap.V216M58
37COSM11411TP53liver,NS,carcinoma,hepatocellular carcinomac.1010G>Tp.R337L58
38COSM100046CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.126A>Gp.T42T58
39COSM142832AXIN1liver,NS,carcinoma,hepatocellular carcinomac.1216G>Tp.E406*58
40COSM12512CDKN2Aliver,NS,carcinoma,hepatocellular carcinomac.262G>Tp.E88*58
41COSM44495TP53liver,NS,carcinoma,hepatocellular carcinomac.559+2T>Ap.?58
42COSM44390TP53liver,NS,carcinoma,hepatocellular carcinomac.838A>Tp.R280*58
43COSM44672TP53liver,NS,carcinoma,hepatocellular carcinomac.658T>Ap.Y220N58
44COSM44511TP53liver,NS,carcinoma,hepatocellular carcinomac.753C>Ap.I251I58
45COSM250744RPS6KA3liver,NS,carcinoma,hepatocellular carcinomac.676T>Ap.Y226N58
46COSM5667CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.134C>Tp.S45F58
47COSM5662CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.110C>Tp.S37F58
48COSM43687TP53liver,NS,carcinoma,hepatocellular carcinomac.641A>Gp.H214R58
49COSM10727TP53liver,NS,carcinoma,hepatocellular carcinomac.438G>Ap.W146*58
50COSM43841TP53liver,NS,carcinoma,hepatocellular carcinomac.560-1G>Tp.?58

Copy number variations for Hepatocellular Carcinoma from CNVD:

6 (show top 50)    (show all 259)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1137721134600000DeletionHepatocellular carcinoma
2145131109179833109180141Copy numberFAM102BHepatocellular carcinoma
3145151109194253109194520Copy numberC1orf59Hepatocellular carcinoma
4164381124300000247249719GainHepatocellular carcinoma
5174011142600000165500000AmplificationHepatocellular carcinoma
6174041142600000207200000GainHepatocellular carcinoma
7193281149600000153300000GainADARLiver carcinoma
8193291149600000153300000GainC1orf43Liver carcinoma
9193301149600000153300000GainHAX1Liver carcinoma
10193311149600000163800000GainHepatocellular carcinoma
1120083115300000184000000GainTAGLN2Hepatocellular carcinoma
12206101153300000154800000GainCCT3Liver carcinoma
13208471154800000157300000GainCD1CLiver carcinoma
14208831155000000165500000AmplificationHepatocellular carcinoma
15212051157300000158800000GainNCSTNLiver carcinoma
16219831163800000165500000GainHepatocellular carcinoma
17221341165500000185800000AmplificationHepatocellular carcinoma
18236811172900000185800000AmplificationHepatocellular carcinoma
19251051184000000212100000LossPTPRCHepatocellular carcinoma
20256281192100000197500000GainCFHR2Liver carcinoma
21261511197500000205300000GainHepatocellular carcinoma
22262781198700000214500000AmplificationHepatocellular carcinoma
23262831198700000249250621GainHepatocellular carcinoma
24284991222700000225100000GainPYCR2Liver carcinoma
25298271236600000243700000AmplificationHepatocellular carcinoma
26298671237459374237459731Copy numberRYR2Hepatocellular carcinoma
273294714071084640711321Copy numberHepatocellular carcinoma
283359414650000060900000LossTGFBR3Hepatocellular carcinoma
293395315070000061300000DeletionHepatocellular carcinoma
30344708101232014101235406Copy numberPOLR2KLiver carcinoma
313582016779066567791040Copy numberIL12RB2Hepatocellular carcinoma
323583216790609367906510Copy numberHepatocellular carcinoma
33361081720000016200000Copy numberMTORHepatocellular carcinoma
3437059184900000117800000DeletionHepatocellular carcinoma
35381861016700000GainAKR1C3Hepatocellular carcinoma
363890210105800000135534747AmplificationHepatocellular carcinoma
3739998101230000017300000LossMRC1Hepatocellular carcinoma
3842451103440000038000000AmplificationC10orf9Hepatocellular carcinoma
3942452103440000038000000AmplificationCREMHepatocellular carcinoma
4042453103440000038000000AmplificationCUL2Hepatocellular carcinoma
4142454103440000038000000AmplificationCX40.1Hepatocellular carcinoma
4242455103440000038000000AmplificationFZD8Hepatocellular carcinoma
4342456103440000038000000AmplificationPARD3Hepatocellular carcinoma
4442799104020000042300000DeletionHepatocellular carcinoma
454832511121700000AmplificationHepatocellular carcinoma
46483531112800000Copy numberIGF2Hepatocellular carcinoma
474988111111568063111568201Copy numberSIK2Hepatocellular carcinoma
485002211112800000127400000LossSORL1Hepatocellular carcinoma
4957131116310000076700000LossESRRAHepatocellular carcinoma
5057452116340000077100000DeletionHepatocellular carcinoma

Expression for genes affiliated with Hepatocellular Carcinoma

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Hepatocellular Carcinoma patients vs. healthy controls: 35
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1EIF3Heukaryotic translation initiation factor 3, subunit HLiver+4.390.000
2C9complement component 9Liver-4.360.000
3UBDubiquitin DLiver+3.390.000
4PSMD6proteasome 26S subunit, non-ATPase 6Liver+3.230.000

Search GEO for disease gene expression data for Hepatocellular Carcinoma.

Pathways for genes affiliated with Hepatocellular Carcinoma

About this section

Pathways related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 68)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
10.9APC, AXIN1, CASP8, CCND1, CTNNB1, HNF1A
210.9APC, AXIN1, CASP8, CCND1, CTNNB1, MET
3
Show member pathways
10.8APC, AXIN1, CCND1, CTNNB1, MET, MYC
410.8APC, AXIN1, CCND1, CTNNB1, MYC, PIK3CA
5
Show member pathways
10.8APC, AXIN1, CCND1, CTNNB1, MYC, PIK3CA
610.8APC, AXIN1, CCND1, CTNNB1, HNF1A, MYC
710.8APC, CCND1, MET, MYC, PIK3CA, TP53
810.8CCND1, CTNNB1, MET, MYC, PIK3CA, TP53
9
Show member pathways
10.7APC, AXIN1, IGF2R, MET, PIK3CA, TP53
10
Show member pathways
10.7CASP8, CTNNB1, IGF2R, MET, PIK3CA, TP53
11
Show member pathways
10.7APC, CTNNB1, MET, PIK3CA, TP53, VEGFA
1210.7APC, AXIN1, CTNNB1, HNF1A, MYC, PIK3CA
13
Show member pathways
10.7CASP8, CCND1, CTNNB1, MYC, PIK3CA, TP53
1410.7APC, AXIN1, CCND1, CTNNB1, MYC, TP53
15
Show member pathways
10.7APC, AXIN1, CCND1, CTNNB1, MYC, TP53
1610.7APC, CCND1, CTNNB1, MYC, PIK3CA, TP53
1710.7AFP, APC, AXIN1, CCND1, CTNNB1, MYC
1810.7CCND1, MET, MYC, PIK3CA, TP53, VEGFA
1910.7APC, AXIN1, CCND1, CTNNB1, HNF1A, MYC
2010.7CASP8, CCND1, CTNNB1, MYC, TP53, VEGFA
2110.7APC, CCND1, CTNNB1, MYC, TP53, VEGFA
22
Show member pathways
10.7AXIN1, CASP8, MYC, PIK3CA, TP53
23
Show member pathways
10.7AXIN1, CCND1, MET, MYC, TP53
24
Show member pathways
10.7CCND1, MET, MYC, PIK3CA, TP53
25
Show member pathways
10.7CASP8, CCND1, CTNNB1, PIK3CA, VEGFA
2610.7CCND1, CTNNB1, MYC, PIK3CA, TP53
27
Show member pathways
10.7CCND1, IGF2R, MET, MYC, TP53
2810.7APC, AXIN1, CCND1, CTNNB1, MYC
29
Show member pathways
10.7CCND1, MYC, PIK3CA, TP53, VEGFA
3010.7CCND1, HNF1A, MYC, TP53, VEGFA
31
Show member pathways
10.6APC, AXIN1, CTNNB1, TP53
3210.6APC, AXIN1, CASP8, CTNNB1
3310.6APC, AXIN1, CTNNB1, MET
3410.6AFP, APC, AXIN1, CTNNB1
3510.6AFP, APC, MET, TP53
3610.6CASP8, CCND1, PIK3CA, TP53
3710.6APC, CCND1, PIK3CA, TP53
3810.6AXIN1, CTNNB1, TP53, VEGFA
3910.6CTNNB1, PIK3CA, TP53, VEGFA
4010.6MET, MYC, PIK3CA, TP53
4110.6APC, AXIN1, CTNNB1, MYC
42
Show member pathways
10.6CCND1, MYC, PIK3CA, TP53
4310.6CCND1, MYC, PIK3CA, TP53
44
Show member pathways
10.6CASP8, CCND1, MYC, TP53
45
Show member pathways
10.6APC, CCND1, MYC, TP53
46
Show member pathways
10.6CCND1, CTNNB1, MYC, PIK3CA
4710.6CCND1, CTNNB1, MYC, TP53
4810.6APC, CCND1, CTNNB1, MYC
4910.6AFP, MET, MYC, VEGFA
5010.6CCND1, MYC, TP53, VEGFA

GO Terms for genes affiliated with Hepatocellular Carcinoma

About this section

Cellular components related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytoplasmGO:000573711.9AFP, APC, AXIN1, CASP8, CCND1, CDKN3
2cytosolGO:000582911.7AFP, APC, AXIN1, CASP8, CCND1, CDKN3
3beta-catenin destruction complexGO:003087711.4APC, AXIN1, CTNNB1
4catenin complexGO:001634211.4APC, CTNNB1
5lateral plasma membraneGO:001632811.3APC, AXIN1, CTNNB1
6protein complexGO:004323410.9CASP8, CTNNB1, HNF1A, MYC, TP53
7Wnt signalosomeGO:199090910.6APC, CTNNB1

Biological processes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1canonical Wnt signaling pathwayGO:006007011.4APC, AXIN1, CCND1, CTNNB1, MYC
2cell cycle arrestGO:000705011.3APC, CDKN3, MYC, TP53
3liver developmentGO:000188911.3CCND1, HNF1A, IGF2R, PIK3CA
4beta-catenin destruction complex disassemblyGO:190488611.3APC, AXIN1, CTNNB1
5activation of protein kinase activityGO:003214711.3AXIN1, PIK3CA, VEGFA
6proteasome-mediated ubiquitin-dependent protein catabolic processGO:004316111.3APC, AXIN1, CTNNB1, TP53
7negative regulation of Wnt signaling pathwayGO:003017811.3APC, AXIN1, CCND1
8positive regulation of peptidyl-serine phosphorylationGO:003313811.3AXIN1, PIK3CA, VEGFA
9beta-catenin destruction complex assemblyGO:190488511.3APC, AXIN1
10positive regulation of mesenchymal cell proliferationGO:000205311.3CTNNB1, MYC, VEGFA
11regulation of apoptotic processGO:004298111.3CASP8, CTNNB1, IGF2R, TP53
12entry of bacterium into host cellGO:003563511.3CTNNB1, MET
13mitotic G1 DNA damage checkpointGO:003157111.2CCND1, TP53
14response to estradiolGO:003235511.2CASP8, CCND1, CTNNB1, MYC
15re-entry into mitotic cell cycleGO:000032011.2CCND1, MYC
16Wnt signaling pathwayGO:001605510.6APC, AXIN1, CCND1, CTNNB1

Molecular functions related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:000551511.9AFP, APC, AXIN1, CASP8, CCND1, CDKN3
2identical protein bindingGO:004280211.6APC, AXIN1, CASP8, IGF2R, TP53, VEGFA
3enzyme bindingGO:001989911.5AXIN1, CCND1, CTNNB1, IGF2R, TP53
4I-SMAD bindingGO:007041111.4AXIN1, CTNNB1
5protein heterodimerization activityGO:004698211.4CTNNB1, HNF1A, MYC, TP53, VEGFA
6protein kinase bindingGO:001990111.4APC, AXIN1, CCND1, CTNNB1, TP53
7transcription factor bindingGO:000813411.3CCND1, CTNNB1, HNF1A, MYC, TP53
8protein phosphatase bindingGO:001990311.3CTNNB1, MET, TP53
9ubiquitin protein ligase bindingGO:003162510.7APC, AXIN1, CASP8, MAGEC2, TP53

Sources for Hepatocellular Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet